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Abstract
Blood function defines bleeding and clotting risks and dictates approaches for clinical intervention. Independent of adding
exogenous tissue factor (TF), human blood treated in vitro with corn trypsin inhibitor (CTI, to block Factor XIIa) will generate
thrombin after an initiation time (Ti) of 1 to 2 hours (depending on donor), while activation of platelets with the GPVI-
activator convulxin reduces Ti to ,20 minutes. Since current kinetic models fail to generate thrombin in the absence of
added TF, we implemented a Platelet-Plasma ODE model accounting for: the Hockin-Mann protease reaction network,
thrombin-dependent display of platelet phosphatidylserine, VIIa function on activated platelets, XIIa and XIa generation and
function, competitive thrombin substrates (fluorogenic detector and fibrinogen), and thrombin consumption during fibrin
polymerization. The kinetic model consisting of 76 ordinary differential equations (76 species, 57 reactions, 105 kinetic
parameters) predicted the clotting of resting and convulxin-activated human blood as well as predicted Ti of human blood
under 50 different initial conditions that titrated increasing levels of TF, Xa, Va, XIa, IXa, and VIIa. Experiments with combined
anti-XI and anti-XII antibodies prevented thrombin production, demonstrating that a leak of XIIa past saturating amounts of
CTI (and not ‘‘blood-borne TF’’ alone) was responsible for in vitro initiation without added TF. Clotting was not blocked by
antibodies used individually against TF, VII/VIIa, P-selectin, GPIb, protein disulfide isomerase, cathepsin G, nor blocked by
the ribosome inhibitor puromycin, the Clk1 kinase inhibitor Tg003, or inhibited VIIa (VIIai). This is the first model to predict
the observed behavior of CTI-treated human blood, either resting or stimulated with platelet activators. CTI-treated human
blood will clot in vitro due to the combined activity of XIIa and XIa, a process enhanced by platelet activators and which
proceeds in the absence of any evidence for kinetically significant blood borne tissue factor.
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Introduction
Blood coagulation is a platelet surface catalyzed protease
cascade with autocatalytic amplification and multiple modes of
inhibition [1]. Clotting in vivo is triggered by exposed tissue factor
(TF) during vascular injury or plaque rupture. There is a striking
sensitivity of coagulation to initial conditions of picomolar levels of
TF [2]. Considerable uncertainty exists concerning the relative
roles of circulating concentrations of TF [3,4] and the mecha-
nism(s) of platelet display of active TF via synthesis [4,5], de-
encryption [6] or changes in membrane composition [7]. The
detection of circulating concentrations of activation peptides, such
as F1.2 and fibrinopeptides A and B, inactivation products such as
thrombin-antithrombin (TAT) [8,9,10,11] and activated factors
such as VIIa and activated Protein C (APC) is proof of some low
level of activated proteases in normal individuals coexisting with
flowing blood in vivo. Exploring this endogenous ‘‘engine-idling’’
active state of human blood ex vivo is central to clinical diagnostics.
From a systems biology perspective that seeks to accommodate
patient-specific variations, modeling can help address central
questions regarding: (i) the regulation of response to perturbation,
(ii) the stability of blood in vivo or ex vivo in the face of zero or near-
zero levels of active TF or active proteases, and the (iii) safe
pharmacological alteration of blood function.
Once initiated with TF, the coagulation cascade proceeds by
sequential enzymatic steps to produce thrombin, which in turn
polymerizes fibrinogen to fibrin to form the protein polymer mesh
of the thrombus. Thrombin also has complex regulatory action by
activating platelets and further enhancing thrombin formation by
activating V, VII, VIII, and XI. In vivo, thrombin can limit its own
production by binding thrombomodulin and converting protein C
to activated protein C (APC), which subsequently inhibits Va and
VIIIa. Upon activation, platelets express anionic phospholipids on
their surface, an event that is critical for several surface bound
reactions of the cascade [12].
Given the central role of thrombin in clotting, much effort has
focused on experimentally detecting the transients of thrombin
generation [13]. ‘Calibrated Automatic Thrombography’ mea-
sures thrombin formation by following the cleavage of more than
100 mM of the thrombin substrate Z-Gly-Gly-Arg-MCA [14].
However, the use of this fluorogenic substrate has been shown to
interfere with the kinetics of the cascade by competitive inhibition
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ulants such as citrate may influence conclusions drawn from
experiments with whole blood [16]. Complications due to artificial
material activation of the contact pathway in vitro can be
minimized by the inhibition of the contact system through the
use of CTI to inhibit XIIa [17].
We have built upon the existing Hockin-Mann reaction network
of the extrinsic coagulation cascade [18] to predict the function of
blood studied in vitro with contact pathway inhibition. The Hockin-
Mann model is a homogenous ordinary differential equation
(ODE) reaction scheme that assumes a maximally activated
platelet at t=0. The Hockin-Mann model predicts accurately the
initiation times of blood coagulation at picomolar levels of TF, but
breaks down at zero or sub-picomolar levels of exogenously added
TF [19]. Other models have attempted to consider the platelet as a
separate entity which exists in discrete activation states and
contributes binding sites once activated for the catalysis of several
coagulation reactions [20,21]. Such approaches have shed light on
the critical importance of platelet activation mediated changes on
the reaction surface area, the fragility of the cascade to thrombin
induced activation of the platelet, stochastic effects at low
molecular counts and experimentally observed variability in the
initiation of clotting. However, these models still do not explain
why blood drawn into CTI will clot without exogenous addition of
TF.
Quantitatively, the systems biology analysis of blood clotting
must account for strong autocatalytic feedback, nonlinearity of
kinetic rates, and extreme sensitivity to initial conditions,
specifically to help predict system outcomes that lead to insufficient
or overactive responses (i.e. bleeding or thrombosis). The present
study explores the stability of normal donor blood (i.e. what tips
the balance towards clotting) as indicated by prolongation or
reduction of the clotting time. We have developed and validated a
high throughput assay to measure thrombin production initiation
in static blood under minimal inhibitory influences of fluorogenic
substrate and anticoagulant. We used this assay to examine several
possibilities in existing literature that could account for initiation
without exogenous TF and conclude that a leak of XIIa past
saturating CTI is responsible for such initiation. Further, our
studies demonstrated blood’s graded sensitivity to exogenously
added TF, IXa and XIa; a dramatic switch like response to
exogenously added Xa; little discernible effect of exogenously
added Va; and statistically significant VIIa activity (independent of
TF) when used above nanomolar concentrations.
Results
We have used a high throughput fluorogenic assay to measure
coagulation initiation in 384-well plates where 56-diluted, citrated
human blood (CTI treated) was recalcified within 5 min of
venipuncture (Figure 1A). A level of 5% cleavage of the
fluorogenic substrate Boc-VPR-MCA was used as the coagulation
initiation time (Ti). A large burst in thrombin production was
always detected within minutes after Ti. Relative prolongation or
reductions in Ti were used to quantify coagulation initiation in
response to varying conditions (Figure 1B). The observed bursts
in fluorescence were completely abolished by the thrombin
inhibitor PPACK, and were not observed in prothrombin deficient
(platelet supplemented) plasma (not shown), proving that we were
indeed detecting thrombin and not some other non specific
protease mediated cleavage of the fluorogenic substrate.
The Platelet-Plasma model (Figure 2 and Tables 1 and 2)
was built on the existing framework of the Hockin-Mann model
[18] and our experimental observations. During the course of
thrombin generation in the well plate, platelets become activated
and this activation was modeled using a coarse-grained description
of platelet function by equating platelet activation (e)t o
phosphatidylserine (PS) exposure as a function of thrombin
concentration (Figures 2B and 2C). The complete topology of
the model, its constituent reactions, and initial conditions are
shown in Figure 2 and Tables 1 and 2 (Also see Supporting
Text S1 for full listing of ODEs and reactions.) Justifications for
making additions to the reaction topology of the Hockin-Mann
structure are explained after the relevant experimental observa-
tions. Justifications for alterations to reaction kinetics are explained
in the footnotes to Table 1.
Validation of experimental methods to detect thrombin
dynamics
Calibrated Automatic Thrombography (CAT) [14] measures
the initiation, propagation and destruction phases of the
thrombogram. In seeking to trace the complete profile, CAT uses
a thrombin substrate Z-GGR-MCA that binds weakly
(Km=305 mM) and that is consumed slowly (kcat=1.86 s
21) and
requires high concentrations (416 mM) to quantify the complete
profile. However, fluorogenic substrates can act as competing
substrates for thrombin, thereby slowing down positive feedback.
Z-GGR-MCA can also serve as a competitive substrate for Xa.
The magnitude and importance of such inhibitory mechanisms of
Z-GGR-MCA are still debated [15,22]. Since thrombin has a
strict requirement for proline in the P2 position [23], we compared
Z-GGR-MCA with the highly selective thrombin substrate Boc-
VPR-MCA (Km=61mM, kcat=53.8 s
21) used at [SIIa] , Km to
detect coagulation initiation.
Titrations of the fluorogenic substrates Boc-VPR-MCA and Z-
GGR-MCA were carried out at 0 and 1 pM added TF
(Figures 3A and 3B) to determine the initiation time (Ti). Since
increasing substrate will take increasing time to be consumed, the
5% conversion criterion (see Methods) cannot be used as the metric
to quantify coagulation initiation. We defined instead, the time
when the second derivative of fluorescence was maximized as Ti
for this experiment. Without addition of TF (Figure 3A), the use
Author Summary
Clotting of blood involves a series of reactions wherein at
each step an inactive zymogen is converted to an active
enzyme by the product of the previous step, sometimes in
plasma and usually on efficient catalytic surfaces provided
by the activating platelet. The protein Tissue Factor (TF)
initiates this cascade when blood vessels are disrupted,
but how this cascade is triggered in the absence of
exogenous TF remains the subject of much debate. First,
we validated a high throughput experimental system that
allowed the noninvasive quantification of thrombin
generation dynamics. Next, we showed that ‘‘contact
activation,’’ despite use of the best available inhibitor (CTI)
to prevent it, builds up enough autocatalytic strength to
trigger coagulation without exogenous TF, particularly
upon activated platelets. Further, we build an ODE based
model to predict the stability of blood resulting from
multiple perturbations with active enzymes at various
physiologically realizable concentrations. Unlike existing
models, we consider the dynamics of platelet activation on
reaction rates due to phosphatiylserine exposure. The
‘‘Platelet-Plasma’’ model lays the groundwork for integra-
tion of coagulation reaction kinetics and donor specific
descriptions of platelet function.
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concentrations from 1 to 100 mM in comparison to Boc-VPR-
MCA. At 1 pM added TF (Figure 3B), both fluorogenic
substrates were found to be inhibitory to some degree as
demonstrated by a prolongation in Ti with increasing substrate
concentration. However, Z-GGR-MCA caused a prolongation of
Ti from 13.1 to 33.8 min as substrate concentration was increased
from 1 to 100 mM, while Boc-VPR-MCA prolonged Ti from 4.1 to
14.0 min as fluorogenic substrate concentration was increased
from 1 to 100 mM. Thus, Boc-VPR-MCA used at up to 100 mM
provided smaller Ti (less inhibition) when compared to Z-GGR-
MCA even when used at 1 mM.
Thrombin-antithrombin (TAT) formation provided an inde-
pendent method to validate the fluorogenic assays (Figures 3C
and 3D). Saturation of the detector (at maximized gain to detect
low substrate concentrations) prevented the testing of 416 mMZ -
GGR-MCA typical of CAT, thus the use of 100 mM Z-GGR-
MCA in this comparison. In the absence of added TF (Figure 3C)
clotting initiation was observed in ,90 min as indicated by a
change from baseline levels of TAT. The addition of 10 mM Boc-
VPR-MCA or 100 mM Z-GGR-MCA slowed the formation of
TAT with 0 or 1 pM TF addition compared to reactions without
fluorogenic substrate (Figures 3C and 3D). In the presence of
1p MT F( Figure 3D), clotting initiated at [TAT],10 nM at a
time between 5 to 10 min in the absence of substrate or with
10 mM Boc-VPR-MCA present. However, clotting initated at
[TAT],10 nM at a time between 10 to 30 min with 100 mMZ -
GGR-MCA present. TAT formation in the propagation phase of
thrombin production was inhibited by the presence of 100 mMZ -
GGR-MCA substrate. Importantly, we have verified that [TAT]
at the time of Ti detected by the fluorogenic assay with 10 mM
Boc-VPR-MCA was 10 to 20 nM which was in excellent
agreement with the initiation phase of coagulation as defined by
the time it takes to generate 10 nM thrombin [24].
The use of a more selective substrate Boc-VPR-MCA at a low
concentration of 10 mM (used for the remainder of this study)
allows for accurate detection of only the initiation phase and not
the entire thrombogram, due to the rapid consumption of the
substrate much before the complete conversion of prothrombin.
However, the time taken for onset of initiation of thrombin
generation is one of the most important characteristic of a
thrombogram, and the use of the substrate at low levels allows for
accurate detection of this metric without appreciable competitive
inhibition of thrombin.
This was the basis for adding the thrombin detection chemistry
(Reaction 28, Table 1) to the Hockin-Mann topology. In
keeping with our experimental observation, thrombin formation is
slightly inhibited by thrombin occupying the fluorogenic substrate
and thus unavailable to generate positive feedback upon the
zymogens V, VII, VIII, XI or activating the platelet.
The nonspecific effects of citrate [16] and CTI [25] were also
evaluated by performing a titration of TF into blood drawn into
CTI alone, CTI-citrate, or citrate alone (Figure 3E). Recalcifi-
cation was done to adjust the concentrations of Ca
2+ in each of
these citrated blood samples to 10 mM. The time difference
between recalcification of all the samples to the same [Ca
2+] and
the drawing of uncitrated blood (which was free to coagulate in the
presence of physiological Ca
2+ concentrations) was less than
3 min. It has recently been suggested that coagulation studies done
with recalcified citrated blood are potentially influenced by
inhibitory effects of calcium citrate [16]. Similarly, CTI has been
reported to interfere with factor VIII coagulant activity [25]. We
Figure 1. High throughput 384-well plate measurement of thrombin production in human blood. (A) Experimental protocol. Calcium
and the fluorogenic thrombin substrate (SIIa) were added to the 384-well plate on a Thermo Multidrop. The plate was placed on a Perkin-Elmer Janus
where various concentrations of each individual species were added to each well. After the blood was drawn, the plate was moved to a Perkin-Elmer
Evolution P
3 where the blood was added to all wells simultaneously (t=0). The plate was read in a Thermo-Electron Fluoroskan where the
fluorescence was measured for 4 hr. The time from vein to first measurement was under 5 min. (B) Initiation Time. The time required to reach 5%
conversion of the fluorogenic substrate was set as the initiation time (Ti). This metric correlated well with ,10 nM TAT and preceded a burst of
thrombin and a maximization of the second derivative of fluorecense. Relative prolongation or reductions in Ti were used to quantify coagulation
initiation.
doi:10.1371/journal.pcbi.1000950.g001
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TF in blood anticoagulated with CTI alone or CTI-citrate,
indicating little inhibitory influence of citrate on the initiation of
coagulation. In the absence of added CTI, the effects of contact
pathway-induced production of XIIa were apparent only below
100 fM added TF as suggested by a lowering of Ti in the absence
of CTI. It should be noted that citrated blood is maintained for
,5 min prior to recalcification in the current study.
Coagulation initiation without added TF
CTI additions beyond 32 mg/ml have been reported to saturate
prolongations of clot times due to contact activation in otherwise
unstimulated blood [1]. We reproducibly observe (Figure 4) that
blood drawn into 50 mg/ml CTI will still clot between 60 to
120 minutes without addition of TF, for all donors tested. Prior
activation of platelets with CVX will lower initiation time to
,20 minutes. Similar results were obtained with other platelet
agonists such as PAR1 peptide agonists or ADP (data not shown).
Since contact activation is thought to be completely inhibited by
the use of CTI, it was reasonable to hypothesize that TF from
some ‘‘blood borne’’ source or other proximal triggers of
prothrombinase formation were responsible for such initiation.
Evaluating the role of ‘blood-borne’ TF and other
mechanisms that could lead to initiation of clotting in
blood drawn into CTI without exogenous TF addition
To evaluate the effect of phlebotomy as a source of vessel wall
derived TF, experiments were conducted with the first 10 ml, 10–
20 ml, 20–30 ml and 30–40 ml of blood (Figure 5A). If TF was
indeed produced from the phlebotomy, an increase in initiation
time would be expected with subsequent volumes of blood drawn
after the initiation of phlebotomy. Clotting initiated in the first
10 ml of resting blood in ,75 min. For all subsequent volumes
clotting initiated at ,90 min and no further increase in initiation
times was observed. Initiation occurred in 25 min in CVX
pretreated blood for all volumes after the blood draw. The amount
of TF due to phlebotomy appears minor and has no role in blood
activated with CVX. In subsequent experiments, the first 10 ml of
blood drawn was discarded.
P-selectin is expressed on the platelet surface upon activation
and induces procoagulant PS exposure [26] and TF synthesis in
monocytes [27]. TF-containing microparticles (MPs) have been
reported to be generated by interactions between P-selectin and
PSGL-1. Furthermore the presence of P-selectin on activated
platelets helps to recruit these MPs to the developing thrombus
[28]. However, the addition of a function-blocking P-selectin
antibody caused no change in the time when a thrombin burst was
detected, in the absence or presence of CVX (Figure 5B). VIIa
can bind weakly to activated platelet surfaces and support
thrombin generation independently of TF [29]. Weeterings et al.
have reported recently that GP1ba can bind rFVIIa with a Kd of
,20 nM and this interaction enhanced TF-independent thrombin
generation [30]. However, neither antibodies against VII/VIIa
(Figure 5E), nor antibodies against GP1ba (Figure 5B) had any
effect on the initiation of thrombin formation with or without
CVX stimulation. Protein disulfide isomerase (PDI) has been
suggested as a possible trigger for tissue factor dependent fibrin
generation. PDI originating from adhering platelets [31] can
activate ‘encrypted or cryptic’ [6] functionally inactive TF by
changing the disulfide status of the Cys186–Cys209 pair on the TF
molecule [32]. Fibrin formation, following infusion of TF
microparticles were shown to be strongly inhibited by an anti-
PDI antibody in vivo [33]. However, in our hands an anti-PDI
antibody had no significant effect in prolonging Ti with or without
CVX treatment (Figure 5C), suggesting that mediated TF de-
encryption via PDI was not a mechanism at play. This is consistent
with earlier reports that: (1) exogenously added PDI or anti-PDI
antibodies had no effect on TF-VIIa coagulant activity shown by
MDA-MB231 cells stimulated with HgCl2; or (2) PDI silencing
with PDI shRNA had no effect on procoagulant activity [34]. The
integrin Mac-1 (CD11b/CD18) on neutrophils or monocytes can
bind FX which can be converted to Xa by cathepsin G.
Inflammatory stimuli or Mac-1 engagement of its ligands
(including fibrinogen and FX) stimulates degranulation and release
of cathepsin-G [35]. Such a mechanism of X activation could lead
to initiation in the absence of TF. However, the addition of a anti-
cathepsin G antibody had no effect in prolonging the time at
which a burst in thrombin production occurred with or without
CVX treatment (Figure 5C).
Platelets may have the capacity to rapidly splice TF pre-mRNA
to a mature transcript and rapidly translate TF protein
intracellularly [36]. We added Tg003 and puromycin to inhibit
Cdc2-like kinase (Clk)1 and ribosomal function, respectively, two
platelet functions reported to be responsible for splicing TF pre-
mRNA and rapid TF mRNA translation [36]. A level of 10 mM
Tg003 and 5 mM puromycin had no effect on the initiation time
(Figure 5D), either in the absence or presence of high dose CVX.
This suggests that the capacity of platelets to splice TF pre-mRNA
and rapidly express TF protein does not contribute to clotting
initiation at least on the time scales of the experiment. Also, the
addition of 20 mg/ml anti-TF, 20 mg/ml anti-VII/VIIa
(Figure 5E)o r1 mM active site inhibited factor VIIa, VIIai
(Figure 5F) caused no increase in Ti with or without CVX
activation of the platelets. This further suggests that in whole blood
endogenous TF mediated mechanisms are not responsible for
clotting initiation.
We note that in all experiments utilizing antibodies and without
prior platelet activation there was slight reduction (relative to the
control where no antibody was added) in the time taken for
initiation to occur. For instance, sheep IgG by itself reduces Ti
(Figure 5B) from 91.82613.35 (control) to 70.08610.57 min.
Such effects were possibly mediated by non specific Fcc-R
mediated platelet activation [37] and were not apparent when
the platelets were already fully activated with CVX.
Evaluating the role of CTI
In the absence of evidence for kinetically-significant blood borne
TF, we evaluated the efficacy of high concentrations of CTI
(Figure 6). Without inclusion of CTI in the syringe or in the well
plate, clotting initiated in 57.369.9 min. When 10 mg/ml CTI
(final concentration) was included in the well plate, initiation
occurred in 77.467.0 min due to inhibition of XIIa production.
Figure 2. Schematic of the Platelet-Plasma model. (A) Wiring diagram of the Platelet-Plasma model. Blue highlighted portions represent
additions to the Hockin-Mann model [18]. (B) Phosphatidylserine exposure measured by fold increase in annexin V binding was obtained from
published values [60] and are shown in blue circles. The maximum platelet activation state attainable at a given thrombin concentration (emax) was
obtained by fitting a hill function to this data (green line). (C) The instantaneous platelet activation status (e) approaches its maximum attainable value
(emax) on a time scale consistent with the time it takes for the platelet to mobilize intracellular calcium. Shown are e transient profiles at various values
of emax.( See text for complete mathematical descriptions of emax and e).
doi:10.1371/journal.pcbi.1000950.g002
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Rxn Model Expressions k1 k21 kcat (s
21)
Hockin-Mann
Model Km or
Kd (M) g
Platelet-Plasma
Model (e=1)K m
or Kd (M) References
1 TF + VII « TF=VII 3.2610
6 M
21 s
21 3.1610
23 s
21 9.6610
210 10 9.6610
29 [61,62]
2 TF + VIIa « TF=VIIa 2.3610
7 M
21 s
21 3.1610
23 s
21 1.3610
210 0.01 1.3610
212 [63]
3 TF=VIIa + VII R TF=VIIa + VIIa 4.4610
5 M
21 s
21
4 Xa + VII R Xa + VIIa 1.3610
7 M
21 s
21
5 IIa + VII R IIa + VIIa 2.3610
4 M
21 s
21
6 TF=VIIa + X « TF=VIIa=X R TF=VIIa=Xa 2.5610
7 M
21 s
21 1.05 s
21 6 2.8610
27 0.01 2.4610
27 [63,64]
7 TF=VIIa + Xa « TF=VIIa=Xa 2.2610
7 M
21 s
21 19 s
21 8.6610
27 1 8.6610
27 [65]
8 TF=VIIa + IX « TF=VIIa=IX R TF=VIIa + IXa 1.0610
7 M
21 s
21 2.4 s
21 1.8 4.2610
27 1 4.2610
27 [66]
9 II + Xa R IIa + Xa 7.5610
3 M
21 s
21
10 IIa + VIII R IIa + VIIIa 2.0610
7 M
21 s
21
11 VIIIa + IXa « IXa=VIIIa 1.0610
7 M
21 s
21 5.0610
23 s
21 5.0610
210 0.02 1.0610
211 [67,68]
12 IXa=VIIIa + X « IXa=VIIIa=X R IXa=VIIIa + Xa 1.0610
8 M
21 s
21 1.0610
23 s
21 8.2 8.2610
28 0.01 8.2610
28 [69]
13 VIIIa « VIIIa1NL + VIIIa2 6.0610
23 s
21 2.2610
4 M
21 s
21 2.7610
27 0.01 2.7610
29 [70,71]
14 IXa=VIIIa=X R VIIIa1NL + VIIIa2 + X + IXa 1.0610
23 s
21
15 IXa=VIIIa R VIIIa1NL + VIIIa2 + IXa 1.0610
23 s
21
16 IIa + V R IIa + Va 2.0610
7 M
21 s
21
17 Xa + Va « Xa=Va 4.0610
8 M
21 s
21 0.2 s
21 5.0610
210 0.04 2.0610
211 [72]
18 Xa=Va + II « Xa=Va=II R Xa=Va + mIIa 1.0610
8 M
21 s
21 103 s
21 63.5 1.6610
26 0.02 6.5610
27 [73]
19 Xa=Va + mIIa R Xa=Va + IIa 1.5610
7 M
21 s
21
20 Xa + TFPI « Xa=TFPI 9.0610
5 M
21 s
21 3.6610
24 s
21 4.0610
210 1 4.0610
210 [74]
21 TF=VIIa=Xa + TFPI « TF=VIIa=Xa=TFPI 3.2610
8 M
21 s
21 1.1610
24 s
21 3.4610
213 100 3.4610
211 [64]
22 TF=VIIa + Xa=TFPI R TF=VIIa=Xa=TFPI 5.0610
7 M
21 s
21
23 Xa + ATIII R Xa=ATIII 1.5610
3 M
21 s
21
24 mIIa + ATIII R mIIa=ATIII 7.1610
3 M
21 s
21
25 IXa + ATIII R IXa=ATIII 4.9610
2 M
21 s
21
26 IIa + ATIII R IIa=ATIII 7.1610
3 M
21 s
21
27 TF=VIIa + ATIII R TF=VIIa=ATIII 2.3610
2 M
21 s
21
28 Boc-VPR-MCA + IIa « Boc-VPR-MCA-IIa R
Boc-VPR + AMC + IIa
1.0610
8 M
21 s
21 6.1610
3 s
21 53.8 - 6.1610
25
29 XII R XIIa 5.0610
24 s
21
30 XIIa + XII « XIIa=XII R XIIa + XIIa 1.0610
8M
21 s
21 750 s
21 3.3610
22 - 1 7.5610
26 [75,76]
31 XIIa + PK « XIIa=PK R XIIa + K 1.0610
8M
21 s
21 3.6610
3 40 - 1 3.7610
25 [75,77]
32 XII + K « XII=K R XIIa + K 1.0610
8M
21 s
21 45.3 s
21 5.7 - 1 5.1610
27 [75,78]
33 PK + K R K + K 2.7610
4M
21 s
21 - [79]
34 K R K.Inhibited 1.1610
22 s
21 [80]
35 XIIa + CTI « XIIa=CTI 1.0610
8 M
21 s
21 2.4 s
21 - - 2.4610
28 [17]
36 XIIa + C1inh R XIIa=C1inh 3.6610
3 M
21 s
21 [81]
37 XIIa + ATIII R XIIa=ATIII 21.6 M
21 s
21 [81]
38 XI + IIa « XI-IIa R XIa + IIa 1.0610
8 M
21 s
21 5s
21 1.3610
24 - - 5.0610
28 [82,83]
39 XIIa + XI « XIIa=XI R XIIa + XIa 1.0610
8 M
21 s
21 200 s
21 5.7610
24 - 1 2.0610
26 [78,82]
40 XIa + XI « XIa=XI R XIa + XIa 3.19610
6M
21 s
21 [46,82]
41 XIa + ATIII R XIa=ATIII 3.2610
2 M
21 s
21 [84]
42 XIa + C1inh R XIa=C1inh 1.8610
3 M
21 s
21 [84]
43 XIa + a1AT R XIa=a1AT 1.0610
2 M
21 s
21 [84]
44 XIa + a2AP R XIa=a2AP 4.3610
3 M
21 s
21 [84]
45 XIa + IX « XIa-IX R XIa + IXa 1.0610
8 M
21 s
21 41 s
21 7.7 - 1 4.9610
27 [85,86]
46 IXa + X « IXa=X R IXa + Xa 1.0610
8M
21 s
21 0.64 s
21 7.0610
24 - 1 6.4610
29 [69,87,88]
47 Xa + VIII « Xa=VIII R Xa + VIIIa 1.0610
8 M
21 s
21 2.1 s
21 0.023 - 1 2.1610
28 [68,89,90]
48 VIIa + IX « VIIa=IX R VIIa + IXa 1.0610
8 M
21 s
21 0.9 s
21 3.6610
25 -9 610
29 [91]
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21)
Hockin-Mann
Model Km or
Kd (M) g
Platelet-Plasma
Model (e=1)K m
or Kd (M) References
49 VIIa + X « VIIa=X R VIIa + Xa 1.0610
8 M
21 s
21 210 s
21 1.6610
26 - 1 2.1610
26 [91]
50 Fbg + IIa « Fbg=IIa R Fbn1 + IIa + FPA 1.0610
8 M
21 s
21 636 s
21 84 - 7.2610
26 [47]
51 Fbn1 + IIa « Fbn1=IIa R Fbn2 + IIa + FPB 1.0610
8 M
21 s
21 742.6 s
21 7.4 - 7.5610
26 [47]
52 2Fbn1 « (Fbn1)2 1.0610
6 M
21 s
21 6.4610
22 s
21 [47]
53 (Fbn1)2 + IIa « (Fbn1)2=IIaR (Fbn2)2 + IIa + FPB 1.0610
8 M
21 s
21 701 s
21 49 - 7.5610
26 [47]
54 Fbn2 + IIa « Fbn2=IIa 1.0610
8 M
21 s
21 1.0610
3 s
21 - 1.0610
25 [47]
55 (Fbn1)2=IIa + ATIII R (Fbn1)2=IIa: ATIII 1.6610
4 M
21 s
21 [47]
56 Fbn1=IIa + ATIII R Fbn1=IIa: ATIII 1.6610
4 M
21 s
21 [47]
57 Fbn2=IIa + ATIII R Fbn2=IIa: ATIII 1.0610
4 M
21 s
21 [47]
Rxn 1. Bach et al. [61] report a decrease in KH from 14.9 to 0.58 nM as % phosphatidylserine (PS) increases from 0 to 40.
O’Brien et al. [62] report a kassoc of 3.14610
5 M
21 s
21 and a kdiss of 6.29610
24 s
21, which yields a Kd of ,2 nM. With our choice of g,K d is comparable to this value.
Rxn 2. Shaw et al. [63] report a decrease in Kd from ,60 pM to ,10 pM as % PS increases from 10–40. on TF liposomes and a decrease from ,90 pM to ,10 pM as %
PS increases from 10–70 on TF nanodiscs.
Rxn 6. Shaw et al. [63] also report an ,206decrease in Km from ,400 nM to 20 nM for X activation as % PS increases from 10 to 40. Baugh et al. [64] report an
experimental Km of 238 nM on 25% PS vescicles.
Rxn 7. The product inhibition of TF:VIIa by Xa is dependent on local Xa concentrations. Given that Xa and X binding to a PSPC bilayer increases hyperbolically with Kds
of 53.9 and 34.2 nM respectively [65] and that the TF:VIIa:X complex is strengthened with increasing PS content (see 6), it is reasonable to assume that the TF:VIIa:Xa
complex is also strengthened with increasing PS levels.
Rxn 8. Beals et al. [66] report that the Kd for bovine IX binding to lipid surface at optimum [Ca
2 + ] decreases from 4.9 to 1.7 mM as % PS increases from 20 to 50. Given
that the formation of TF:VIIa is favoured with increasing PS content (See 2) and analogous to the increased strength of the TF:VIIa:X complex with increased PS (see 6),
we expect that the formation of TF:VIIa:IX will also increase with increasing PS content.
Rxn 11. Jenkins et al. [67] report a decrease in Kd from 351 nM to 4 nM on PCPS vesicles. Neuenschander and Jesty [68] report a Kd of 74 pM on activated platelet
surfaces as opposed to 550 pM on equimolar PSPC vesicles. A Kd of 10 pM on the activated platelet was required to fit the shape of the IXa titration in Figure 9B.
Rxn 12. Rawala Sheikh et al. [69] report a decrease in Km from 45mM to 160nM from using unactivated to activated platelets respectively.
Rxn 13. Fay et al. [70] report a Kd value of ,260 nM for this interaction at pH 7.4 in the absence of phospholipids. Fay et al. [71] report that this interaction is stabilized
by the presence of phospholipid. In the Platelet-Plasma model this dissociation constant changes from 270 nM to 2.7 nM as the platelet activates.
Rxn 17. Lindhout et al. [72] report a decrease in Kd from 3.3 nM in solution to 30 pM using 10mM 40% PS.
Rxn 18. Rosing et al. [73] report a decrease in Km from 34.5 to 0.21 mM using 7.5 mM phospholipids.
Rxn 20. Huang et al. [74] report a decrease in Ki from 85.2 to 65.2 pM on using phospholipids.
Rxn 21. Given that the TF:VIIa:Xa (see 7) and the Xa:TFPI (see 20) complexes are strengthened on phospholipids, we expect the stabilization of the TF:VIIa:Xa:TFPI
complex with the exposure of phospholipids as the platelet activates.
Baugh et al. [64] report an off rate 3.6610
24 s
21 for Xa unbinding Xa:TFPI, and on rates experimentally determined to be 9.0610
5 M
21s
21, or numerically estimated to
range between 6.8610
5 and 1.35610
6 M
21s
21. Their data imply that these constants are comparable to those for the binding of TF:VIIa:Xa to TFPI (ie a Kd between
2.66610
210 and 5.29610
210 M). The original constants for this reaction in the Hockin-Mann model were fitted empirically, but their choice of constants results in a far
stronger complex than can be reasonably expected from literature. Hence we have increased Kd by two orders (g=100) of magnitude from their reported value.
Rxn 28. Experimentally determined by fitting initial velocities of AMC release to standard Michelis-menton kinetics.
Rxn 29.XII activation was coarse grained by assuming a first order dependence on XII concentration and estimating a rate of production (5610
24s
21) that would
resolve the disparity between the Hockin-Mann model prediction and the experimentally observed control.
Rxn 30. Kinetics of XIIa autoactivation (in the presence of negatively charged dextran sulfate) was from Tankersley et al. [75]. Griep et al. [76] showed that the
autoactivation (and Kallikrein activation, See 32) of XII is strongly promoted by negatively charged sulfatides.
Rxn 31. Kinetics of Pre-Kallikrein activation by b-XIIa (in the presence of dextran sulfate) was from Tankersley et al. [75]. Pre-Kallikrein activation by XIIa was shown to be
facilitated by negatively charged phosphoinositides [77].
Rxn 32. Kinetics of XII activation by Kallikrein (in the presence of dextran sulfate) was from Tankersley et.al [75]. Walsh and Griffin [78] showed that this reaction is sped
up by the presence of activated platelets.
Rxn 33. Kinetics of second order Kallikrein autoactivation was from Tans et al. [79].
Rxn 34. The pseudo first order rate constant for the inhibition of Kallikrein in plasma (by C1 inhibitor, a2-macroglobulin and ATIII) was obtained from Van-Der-Graaf
et al. [80].
Rxn 35. Hojima et al. [17] report a Ki of 24 nM for the inhibition of XIIa by CTI.
Rxns 36 and 37. Kinetics of XIIa inhibition by C1inhibitor and ATIII were from Pixley et al. [81]. C1 inhibitor is the primary inhibitor of XIIa. ATIII inhibition (although
minor) was considering for consistency with other inhibitory reactions.
Rxn 38. Rate constants (in solution) for this reaction are from Gailani et al. [82]. Some controversy exists over the physiological surface for this reaction. Oliver et al. [83]
showed that this reaction happens physiologically on the activated platelet surface. However several seminal papers by Baglia-Walsh et al. in the laboratory of Peter N.
Walsh which originally proposed that this mechanism happens on the active platelet have subsequently been retracted. We therefore chose not to include a
dependence of this reaction on e.
Rxn 39. Rate constants (in solution) for this reaction are from Gailani et al. [82]. Walsh and Griffin [78], showed that this reaction is sped up by the presence of activated
platelets.
Rxn 40. Several authors describe this mechanism of XI auto-activation (See for example [45,82]). However, following the retraction of (Baglia et al. JBC 2000) we are not
aware of an experimental report of the kinetics of this reaction. Kramoroff et al. [46]estimate the second order rate constant of this reaction to be 3.19 mM
21s
21 by
optimizing an ODE model of the intrinsic cascade to experimental measurements of APTT. They consider either XI autoactivation or XI activation by thrombin (but not
both possibilities) as plausible mechanisms for XI activation (in addition to activation by XIIa), thus their estimated value is likely an overestimate. We utilized a value 4
fold lower than the value they report for this constant, since we consider thrombin activation of XI in addition to autoactivation. This was in keeping with the
experimental titration of XIa (Figure 9C) where we have noticed strong sensitivity to even minute amounts of XIa.
Rxns 41–44. Rate constants are for inhibition of XIa in plasma are from Wuillemein et al. [84].
Rxn 45. Rate constants (in solution) for this reaction are from Walsh et al. [85]. Gailani et al. [86] propose a mechanism by which this reaction could happen on the
platelet surface facilitated by the dimeric form of factor XI.
Rxn 46. Rawala - Sheikh et al. [69] report a reduction in Km from 45 mM to 390 nM from unactivated to thrombin activated platelets. In later publications from the same
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dilution of blood in the well plate) by including 50 mg/ml CTI in
the phlebotomy syringe, initiation time was markedly prolonged to
110.0617.0 min. Liquid handling of citrated blood after phlebot-
omy takes ,3 minutes before recalcification and this result points
to the significant production of XIIa during this initial period.
When very high concentrations (100 mg/ml) of CTI were achieved
by including CTI in the syringe (50 mg/ml, diluted 56in the well
plate) and 90 mg/ml preexisting CTI in the well plate, initiation
occurred in 96.6615.1 min and was not prolonged further. Thus,
the inhibitory effect of CTI saturates in spite of its use at very high
concentration pointing to the possibility of a XIIa leak past CTI.
Anti-XI and anti-XII used simultaneously prevent
initiation in resting blood
Combined addition of 50 mg/ml of anti-XI and anti-XII to
diluted whole blood (with CTI) completely abolished initiation
(Figure 7) demonstrating that for conditions lacking platelet
activation a steady leak of XIIa activity past CTI was the most
proximal trigger of platelet activation and subsequent clotting of
minimally perturbed blood in vitro. Interestingly, anti-XII when
used alone did not prevent initiation (not shown), suggesting that
inspite of our best attempts at preventing XII activation in diluted
whole blood (CTI and anti-XII used together), some XIIa is still
formed on the time scale of our experiments, necessitating the
inhibition of XI activity as well. Also, anti-XI by itself did not
prevent initiation in whole blood (not shown), suggesting strong
autocatalytic amplification by very minute amounts of XIa formed
inspite of the use of the inhibitory XI antibody. Despite the
efficacy of high dose CTI in conjunction with anti-XI and anti-XII
in preventing activation in resting blood, there was no effect of
these antibodies on Ti when blood had been treated with CVX.
The levels of thrombin produced during the initial moments of the
propagation phase of thrombin production (after Ti) were however
diminished as demonstrated by lowered rates of fluorescence
increase. This was possibly a consequence of the inhibition of
thrombin- mediated feedback on FXI after initiation [38].
Preventing initiation in CVX treated blood
Unlike the case of resting blood, initiation could not be
prevented in blood pretreated with CVX by the use of antibodies
against XI and XII. To probe further the mechanism responsible
for such initiation, we supplemented CTI-treated regular plasma
and CTI-treated plasmas deficient in factors VII, XI and XII with
washed platelets. Thrombin generation in these samples as well as
samples of plasma that had been treated with antibodies against
TF, VII, XI, XII, or XI/XII/VII was studied following CVX
activation (Figure 8). Antibodies against TF had no detectable
effect. Thrombin formation was not completely inhibited by
blocking any single factor individually, but was inhibited in
samples where the activities of XI, XII and VII were simulta-
neously inhibited (Figure 8, last row of subplots). In particular
clotting was completely inhibited in 6 out of 8 wells in XI-deficient
plasma treated with antibodies against XI, XII and VII. Inhibition
of VIIa activity alone is insufficient (initiation times are almost
unchanged in VII-deficient plasma treated with a VII antibody)
because XIa formation beyond the XIIa leak past CTI, is still
sufficient to trigger thrombin formation. Inhibition of XI activity
(XI-deficient plasma with an XI antibody) has pronounced
inhibitory effect, but was still insufficient with VIIa being
functionally active on the active platelet. Thus upon activated
platelets, in addition to blocking factors XI and XII, VIIa activity
too must be inhibited to prevent thrombin generation.
It should be noted that immunodepleted plasmas deficient in
coagulation factors have ,1% normal activity of the particular
factor, but are still not completely devoid of the depleted protein.
This explains why initiation is prolonged further by antibodies
against a protein that had already been immunodepleted in
plasma. For instance thrombin generation in anti-XI treated, XI-
deficient plasma is inhibited compared to that observed in XI-
deficient plasma alone. The use of deficient plasmas offers a
‘‘cleaner inhibition’’ because the protein being targeted for
inhibition is largely absent from the onset, as opposed to reliance
on the inhibitory antibody to exert its effect before the protein is
functionally active.
Thrombin formation, once clotting is initiated by a single
activator for instance by the addition of TF or Xa (See Figure 9)
yields relatively small variations in initiation time when tested in
multiple replicates. However, given the strongly autocatalytic
nature of the cascade, complete abolition of a triggering
mechanism is much more challenging. Even small localized
diffusional or binding limitations of the inhibitory antibody will
allow individual molecules that bypass the inhibitors to trigger the
cascade. This accounts for the relatively large variations we
observe in trying to inhibit initiation upon activated platelets,
where thrombin formation occurs stochastically past inhibitory
antibodies against targeted coagulation proteins.
Titrations of TF and active proteases into blood
Addition of exogenous lipidated TF was used to initiate
coagulation via the extrinsic pathway. Concentrations from
0.5 fM to 5 pM were added to whole blood (Figure 9A). Added
lab, Scandura and Walsh [87] report a Km of 16nM and a kcat of 5.1610
24 for the activation of X by IXa alone on SFLLRN activated platelets in a model where platelet
bound IXa interacts with zymogen X, and Wilkinson et al. [88] report a Km of 6.4 nM and a kcat of 7.0610
24.
Rxn 47. Rate constants were obtained from Leipold et al. [89] using catalytic efficiencies reported in Lollar et al. [90]. Activation of VIII by Xa, unlike activation by
thrombin (reaction 10) was reported to be markedly dependent on the presence of either phospholipid or active platelet surface [68].
Rxn 48. Rate constants for this reaction were from Komiyama et al. [91]. Unlike the activation of X by VIIa alone (see 49) the Km for this reaction was reported to be
relatively constant over a wide range of added PCPS concentrations, thus unlike other unbinding reactions in the model there was no dynamic change in reaction rate
with platelet activation.
Rxn 49. Rate constants for this reaction were from Komiyama et al. [91]. The authors report a decrease in Km from 1.48 to 0.25 mM with PCPS levels increasing from 1.4
to 21 mM.
Rxns 50–57. Kinetics of fibrin polymerization are taken from Naski et al. [47].
Reactions 1–27 comprise the original Hockin-Mann Model.
For reactions 1–27, parameter values were from the Hockin-Mann model when a reference is not cited.
Except for reaction 13, e wherever applicable operates on the off rate usually defined as k21. For reaction 13, e operates on k1 which is the actual unbinding rate of the
VIIIa complex. The notation for this reaction is kept consistent with its description in the Hockin-Mann Model.
On-Rates were assumed to be diffusion limited (with a k1 of 1.0610
8 M
21 s
21) [20], and the corresponding off-rate was calculated from Km using Km~
koffzkcat
kon
.
doi:10.1371/journal.pcbi.1000950.t001
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initiation time over a wide dynamic range of 3 orders of magnitude
of concentration from 20 fM to 20 pM. Distinct from flow
experiments where a concentration threshold exists between 2 and
20 molecule-TF/mm
2 [39], no switch-like regime was detected
under static conditions. This suggests that the barrier to be
overcome in the flow system to exceed the threshold is not a
chemical inhibition barrier since such a barrier would be present
under stasis as well. The observation is consistent with Fogelson
and Tania [40] who note the barrier responsible for the threshold
under flow is a physical one dependent on competition between
flow-mediated removal and rate of production of procoagulant
species.
Next, we investigated the individual components of prothrom-
binase (XaVa complex) on coagulation initiation (Figure 9B).
Addition of Va showed negligible effects with minimally decreased
initiation time from 0.3 nM to 4 nM added Va (.10% of the
Table 2. Initial conditions of species in the Platelet-Plasma
model.
Species
Hockin-Mann Model
Initial Concentration (M)
Platelet-Plasma Model
Initial Conditions (M)
TF 0 0
VII 1.0610
28 1.0610
28
TF=VII 0 0
VIIa 1.0610
210 1.0610
210
TF=VIIa 0 0
Xa 0 0
IIa 0 0
X 1.6610
27 1.6610
27
TF=VIIa=X 0 0
TF=VIIa=Xa 0 0
IX 9.0610
28 9.0610
28
TF=VIIa=IX 0 0
IXa 0 0
II 1.4610
26 1.4610
26
VIII 7.0610
210 7.0610
210
VIIIa 0 0
IXa=VIIIa 0 0
IXa=VIIIa=X 0 0
VIIIa1-L 0 0
VIIIa2 0 0
V 2.0610
28 2.0610
28
Va 0 0
Xa=Va 0 0
Xa=Va=II 0 0
mIIa 0 0
TFPI 2.5610
29 2.5610
29
Xa=TFPI 0 0
TF=VIIa=
Xa=TFPI
00
ATIII 3.4610
26 3.4610
26
Xa=ATIII 0 0
mIIa=ATIII 0 0
IXa=ATIII 0 0
IIa=ATIII 0 0
TF=VIIa=ATIII 0 0
Boc-VPR-MCA - 1.0610
25
Boc-VPR-MCA=IIa - 0
Boc-VPR - 0
AMC - 0
XII - 3.4610
27
XIIa - 0
XIIa=XII - 0
PK - 4.5610
27
XIIa=PK - 0
K=XII - 0
K- 0
CTI - 4.2610
26
XIIa=CTI - 0
C1inh - 2.5610
26
Species
Hockin-Mann Model
Initial Concentration (M)
Platelet-Plasma Model
Initial Conditions (M)
XIIa=C1inh - 0
XIIa=ATIII - 0
XI - 3.1610
28
XI=IIa - 0
XIa - 0
XIIa=XI - 0
XIa=ATIII - 0
XIa=C1inh - 0
a1AT - 4.5610
25
a2AP - 1.0610
26
XIa=a1AT - 0
XIa=a2AP - 0
XIa=IX - 0
IXa=X - 0
Xa=VIII - 0
VIIa=IX - 0
VIIa=X - 0
Fbg - 9.0610
26
Fbg=IIa - 0
Fbn1 - 0
Fbn1=IIa - 0
(Fbn1)2 -0
(Fbn1)2=IIa - 0
Fbn2 - 0
Fbn2=IIa - 0
(Fbn1)2=IIa=ATIII - 0
Fbn1=IIa=ATIII - 0
Fbn2=IIa=ATIII - 0
The initial conditions for the first 34 values in Table 2, were set to the values
used in the Hockin Mann model [18]. The level of Boc-VPR-MCA was set to
10 mM (this is the level of fluorogenic substrate we use in our experiment). The
level of CTI was set to 4.2 mM corresponding to the concentration of 50 mg/ml
used in the phlebotomy syringe. XII, XI Pre-Kallikrein, C1-Inhibitor, a1AT, a2AP
and Fibrinogen are set to their plasma concentrations [84,92,93].
doi:10.1371/journal.pcbi.1000950.t002
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PLoS Computational Biology | www.ploscompbiol.org 9 September 2010 | Volume 6 | Issue 9 | e1000950Figure 3. Validation of experimental protocol. (A) A titration of the fluorogenic substrates Boc-VPR-MCA (blue circle) and Z-GGR-MCA (green
square) with 0 added TF showed a mild inhibitory influence of Z-GGR-MCA. *s indicates statistically significant difference (p,0.05) between initiation
times detected with the two different substrates. (B) A titration of the fluorogenic substrates Boc-VPR-MCA and Z-GGR-MCA with 1 pM added TF
showed inhibitory influence of both substrates where Boc-VPR-MCA was found to be the better substrate to detect initiation and exhibited little
Systems Biology of Coagulation Initiation
PLoS Computational Biology | www.ploscompbiol.org 10 September 2010 | Volume 6 | Issue 9 | e1000950plasma concentration of V). This relative insensitivity indicated
that Va was not a limiting during coagulation initiation, in
agreement with previous studies that show that Va may be present
in platelets or be rapidly displayed or produced during activation
[41]. In contrast, Xa additions produced a marked switch-like
action by moving from a negligible change in Ti at 10 pM to
nearly saturating effect at 100 pM, a concentration that is ,0.1%
of the plasma concentration of X. This switch-like behavior was
consistent with the well understood rate limiting role of Xa [18].
Further, we explored reactions proximal to thrombin produc-
tion by addition of increasing amounts of Factors VIIa, IXa and
XIa to blood (Figure 9C). The nominal concentrations of
endogenous VIIa (1% of VII) prior to exogenous addition in 56
blood is 20 pM [42]. Using 56final blood dilution, we extended
these concentrations to reach an effective concentration of VIIa
above 1 nM. VIIa has no significant effect until above 1 nM,
approximately 10% of the circulating amount of VII. For
comparison, high dose rVIIa therapies use up to ,17 nM final
concentrations [43]. The dynamic range for added IXa extended
from below 5 pM to above 500 pM and that for XIa extended
from below 2 pM to above 200 pM. The upper end of these
ranges are less than 1% of the circulating IX and XI concentration
respectively [44]. Similar to results for TF, the addition of IXa or
XIa in this assay did not display a switch-like regulatory function,
i.e. changing from no effect to full effect over some narrow
concentration range, but rather displayed a broad dynamic
response over a wide range of concentrations.
Baseline low level protease activity can exist even in healthy
individuals (the ‘‘engine idling’’ theory). Knowledge of the upper
bounds of these proteases defines the levels of these enzymes that
allow blood to remain in a stable state (flowing normally) in spite of
their presence. Experimentally measured values of active proteases
for a patient that are significantly different from these values might
indicate underlying coagulation disorders or heightened sensitivity
to weak triggers of clotting. Knowledge of the upper bound on
proteases also is necessary for the accurate in silico modeling of
human blood studied in vitro.
Platelet-Plasma model of thrombin production in human
blood
The Hockin-Mann model was used to simulate these tirations
and was found to be quite accurate for TF concentrations above
1 pM, but diverged dramatically at concentrations below 1 pM
(Figure 9A, black solid line) of added TF. We have shown
experimentally, that a leak of XIIa past saturating levels of CTI is
responsible for eventual intiation. This prompted us to include the
contact factor pathway to Hockin-Mann topology.
Upon contact with anionic surfaces a conformational change
occurs in the zymogen FXII, resulting in the formation of active
FXIIa. The exact mechanism for XII surface adsorption,
conformation change and activation remain ambiguous and
cannot be modeled easily. We therefore coarse grained surface
mediated XII activation by assuming a first order dependence on
XII concentration (Reaction 29, Table 1) and estimating a rate
inhibition at 10 mM concentration. (C) TAT formation with 0 added TF, in the absence and presence of fluorogenic substrates showed less inhibitory
influence of Boc-VPR-MCA on initiation defined by a burst in TAT compared to Z-GGR-MCA. Absolute [TAT] after initiation is decreased in the
presence of either substrate. (D) TAT formation with 1 pM added TF, in the absence and presence of fluorogenic substrates showed decreased [TAT]
during the propagation phase of coagulation in the presence of either substrate. Initiation detected by TAT correlated well with Ti determined by our
fluorogenic assay. In panels C and D, * indicates [TAT] significantly greater than baseline levels (p,0.05) and # indicates statistically significant
differences compared to no substrate (blue). Experiments in panels A, B, C and D were carried out with blood from the same phlebotomy. (E)T F
titration done in blood anticoagulated with CTI alone (green), Citrate + CTI (red) and Citrate alone (blue). Dashed lines indicate controls with no added
TF. No significant difference was detected in titrations done with and without citrate, showing no evidence of inhibition by the anticoagulant. Effects
of the contact factor pathway were apparent only below 100 fM added TF.
doi:10.1371/journal.pcbi.1000950.g003
Figure 4. Coagulation initiation in the absence of externally added TF. Blood drawn into 50 mg/ml CTI and without added TF, will still
reproducibly clot in ,75 minutes. Prior activation of platelets with CVX will lower initiation time to ,20 minutes. Shown are the multiple replicates
tested under the same conditions with the same phlebotomy.
doi:10.1371/journal.pcbi.1000950.g004
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24s
21) that would resolve the disparity
between the Hockin-Mann model prediction and the experimen-
tally observed control (green) at 0 TF (without disrupting its
predictive ability at high TF). It should be noted that this estimated
rate of XIIa production was based solely on observations in our
experimental surfaces (Corning 384-well plates) and may well be
different on other surfaces. The small amount of XIIa that is
initially formed auto-activates upon negative surfaces in vitro
(Reaction 30, Table 1). Formed XIIa further activates Pre-
Kallikrein to active Kallikrein (Reaction 31, Table 1), which in
turn reciprocally activates XII (Reaction 32, Table 1) and Pre-
Kallikrein (Reaction 33, Table 1). Both Kallikrein and XIIa are
inhibited by plasma protease inhibitors (Reaction 34, 36–37;
Table 1). Further, XIIa is inactivated by CTI included at high
concentrations specifically to inhibit contact activation (Reaction
35, Table 1). Despite the efficacy of CTI, it is a reversible
inhibitor of XIIa; and thus there is always some active XIIa
beyond CTI resulting from the unbinding of the XIIa=CTI
complex. Such XIIa that has ‘‘leaked past’’ CTI can in turn
activate XI (Reaction 39, Table 1). Thrombin feedback on XI
has also been considered (Reaction 38, Table 1) as a mechanism
for XI activation.
We have experimentally observed (Figure 9C) strong
sensitivity of blood to very minute doses of XIa (even 2 pM of
added XI reduced Ti significantly from that of the control). Also
complete abolition of clotting without exogenous TF, required
inhibition of XI activity in addition to XII (Figures 7 and 8)
suggesting that the very little XIa that is formed downstream of
XIIa is able to strongly self amplify (especially if the pro-coagulant
surface of the activated platelet is readily available). With
inhibition by ATIII, C1-inhibitor, a1-antitrypsin and a2-antiplas-
min (Reaction 41–44; Table 1), such sensitivity could not be
adequately explained by just XIIa mediated activation and
thrombin feedback on XI. Therefore we also included the
mechanism of XI auto-activation [45] on negatively charged
surfaces to the topology of the network (Reaction 40, Table 1).
Following the retraction of Baglia and Walsh, JBC 2000 we are
not aware of experimental reports on the kinetics of this reaction.
However, Kramoroff et.al [46] estimate the second order rate
constant of this reaction to be 3.19 mM
21s
21 by optimizing an
ODE model of the intrinsic cascade to experimental measure-
ments of APTT. They consider either XI autoactivation or XI
activation by thrombin (but not both possibilities) as plausible
mechanisms for XI activation (in addition to activation by XIIa),
thus their estimated value is likely an overestimate. We utilized a
value 4-fold lower than the value they report for this constant,
since we consider both mechanisms.
The XIa that is formed activates IX (Reaction 45, Table 1).
Unlike the original Hockin-Mann topology, IXa in the absence of
its cofactor is now able to activate some factor X (Reaction 46,
Table 1) albeit very inefficiently. This minute amount of Xa
contributes to the activation of VIII (Reaction 47, Table 1), in
addition to the VIII activation by thrombin in the Hockin-Mann
structure (Reaction 10, Table 1). VIIIa once formed dramat-
ically raises the efficacy of IXa and hence subsequent thrombin
formation. Thus such participation of Xa in VIII activation (in
addition to its ability to directly convert prothrombin) helps it to
function in simulation as the dramatic switch like controller of the
cascade we observed experimentally (Figure 9B).
VIIa above 1 nM concentrations is able to produce significant
lowering of Ti independently of TF (Figure 9C). Furthermore,
with platelet activation, inhibition of VII activity was required (in
addition to the inhibition of XI and XII activity) to completely
block thrombin generation (Figure 8). This suggests that VIIa
activity independent of TF, is effective at high concentrations and
on the activated platelet. This prompted us to include VIIa’s
ability to convert IX and X (independent of TF) in the structure of
the model (Reactions 48–49; Table 1).
Fibrinogen can act as an efficient sink for thrombin in
experiments conducted in whole blood, and thus limit its ability
to generate positive feedback by converting other zymogens or
activating platelets. The thrombin catalyzed formation of fibrin I
and fibrin II, release of fibrinopeptides A and B and the
irreversible entrapment of thrombin in complexes with fibrin
and antithrombin are described in (Reactions 50–57; Table 1)
using published kinetics [47].
With these additions to the structure of the Hockin-Mann
topology, we could now obtain quantitative agreement between
experimental and simulated titrations of the procoagulant proteins
TF, Va, VIIa, IXa, Xa and XIa into 56 diluted blood. The
original Hockin-Mann topology could predict finite Ti for only
high dose TF/Xa (Solid lines in Figures 9A and B).
Although there is evidence to suggest that TF dependent
reactions (Table 1, Reactions 1, 2, 6–8 and 21) are sped up
on acidic phospholipids (See Comments in footnotes to these
reactions in Table 1), no e dependence was used for these
reactions in our simulations of the TF titration in Figure 9A. This
is because TF was already added in lipidated form in these
experiments, and thus the TF-VIIa assembly or activity will not be
affected by changing lipid composition upon the platelet surface.
The Kuharsky-Fogelson model [20] for thrombin formation
under flow in the presence of collagen activated platelets shows
[Xa] remaining at levels of about 10 pM throughout the duration
of simulation. In the Hockin-Mann model with a TF stimulus of
5 pM, Xa concentrations are 10–100 pM during the times that
substantial thrombin formation first occurs and subsequently this
rises by about 10-fold. Our results, along with the modeling
predictions in these papers suggest why it is necessary that clotting
be sensitive to low levels of Xa in vivo. Namely, if levels produced
under flow (where Xa can be rapidly convected downstream) are
to be efficacious at all, they must produce substantial effects at very
low levels (,10 pM), despite the presence of much higher
concentrations of X, or the system’s ability to produce much
larger concentrations of Xa under conditions of stasis.
Similar to Kuharsky-Fogelson (Figure 7 of reference [20]), we
show in Figure S2 in Text S1 simulations for the concentrations
of thrombin, Xa, Xa:Va, and Va for a stimulus of 5 pM TF (Also,
compare to Hockin-Mann, Figure 8B of reference [18]). We found
free Xa concentrations growing to about 20 pM during the initial
instants followed by a much more substantial burst (that increases
Xa levels by ,3 orders) following platelet activation. The Va
concentrations grow steadily, but beyond full platelet activation
Figure 5. Evaluating mechanisms that could lead to initiation of clotting of blood drawn into CTI without exogenous TF addition.
(A) To evaluate the effect of phlebotomy, experiments were conducted 6CVX using the first 10 mls, 10–20 mls, 20–30 mls and 30–40 mls of blood.
No steady increase in Ti was noted showing that TF from phlebotomy was not leading to eventual initiation. (B) Addition of antibodies against P-
selectin or Gp1ba did not prolong initiation either in the absence or presence of high dose CVX, (C) Addition of antibodies against PDI or cathepsin G
did not prolong initiation either in the absence or presence of high dose CVX. (D) The ribosome inhibitor puromycin; the Clk1 kinase inhibitor Tg003;
(E) antibodies against TF, VII/VIIa; or (F) VIIai did not prolong initiation either in the absence or presence of high dose CVX. This shows that initiation is
unaffected by either ‘bloodborne’ or platelet synthesized TF on the time scales of our experiments.
doi:10.1371/journal.pcbi.1000950.g005
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towards Xa:Va and thus the amount of free Va drops rapidly, as
prothrombinase levels rise steeply.
Simulations of clotting times in whole blood
Our high throughput experimental system allows us to
efficiently study coagulation reactions under various perturbations
with multiple replicates. However, reaction volumes in our 384-
well plate systems are only 50 ml, preventing us from studying
undiluted whole blood. Automated liquid handling can dispense
with high precision volumes of 5 ml, but for lower volumes
experimental variability is high. Since each individual well must
contain several reagents (calcium, fluorogenic substrate, platelet
agonists, antibodies and coagulation proteases) other than human
blood, there is a limitation to the volume of blood that can be used
in each well.
De Smedt et al. [48] have recently reported that anticoagulant
pathways (particularly the TFPI and APC mediated) are more
affected by dilution than the procoagulant pathways. However,
they did not observe any significant effect of dilution on the
duration of the initiation phase, both for TF and Kaolin stimulated
coagulation reactions in PPP upto dilutions of 126 (detectable
effects on endogenous thrombin potential and peak height of the
thrombograms were however reported). Blood at 56final dilution
is below this limit of 126dilution beyond which linear scaling of
initial conditions with the dilution factor might not be sufficient to
account for the kinetics of thrombin generation initiation, and
provides a tractable system for extensive high throughput
experimentation. In simulating such experiments, the initial
conditions of all species were divided by 5 to account for the
dilution in each well.
To test the ability of the model to predict perturbations in whole
blood, we simulated clotting times (a good measure of the time to
generate a burst in thrombin) for additions of either TF; IXa, Xa,
thrombin; or all 3 proteases together reported by Butenas et al.
[49]. We found good agreement between experimentally reported
values of clotting time and predicted initiation times across all
conditions (Figure 10). The original Hockin-Mann model could
predict finite Ti in the presence of high dose TF/Xa, or when low
dose thrombin, IXa and Xa were present simultaneously.
Simulating platelet activation
The Hockin–Mann model assumes a fully activated platelet at
t=0. In the Kuharsky-Fogelson model [20] or the Cellular Potts
model [50], platelets can exist either in discrete ‘‘unactivated’’ or
‘‘activated’’ states. We do not consider platelets explicitly, but all
reaction rates reported in literature to be dependent on platelet
activation are altered by a single function (e) of thrombin
concentration (See Methods). As the platelets are activated by
thrombin, they expose anionic phospholipids like PS on their
surface, and the ‘‘platelet activation status’’ e increases from a
basal state of 0.01 to 1.00. The unbinding rates of all enzyme-
Figure 6. Saturation of the effects of CTI. To evaluate the possibility of leakage past CTI, experiments were conducted with no CTI, CTI addition
in well plate, CTI addition during phlebotomy and large quantities of CTI during phlebotomy as well as in well plate. The inclusion of 50 mg CTI/ml
whole blood (before a 56dilution in the well plate) produced saturating effects.
doi:10.1371/journal.pcbi.1000950.g006
Figure 7. Effect of anti-XI and anti-XII. Addition of 50 mg/ml of anti-XI and anti-XII will completely prevent initiation of clotting in resting blood
showing that initiation is a result of leak past saturated effects of CTI. However, on CVX activated platelets initiation is still unaffected by the presence
of both CTI and these antibodies. Initial thrombin production during the propagation phase is however diminished due to abolition of thrombin
feedback on FXI. Insert shows initial rates of thrombin formation in the presence of these antibodies.
doi:10.1371/journal.pcbi.1000950.g007
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PS levels, but are all divided by e. Thus, as the platelet activates
the unbinding rates dynamically decrease by two orders of
magnitude, consistent with the notion that the platelet surface
becomes more procoagulant. In the Kuharsky-Fogelson model of
intravascular thrombosis under flow, reaction rates depend on the
availability of fully activated platelets (contributing maximal
platelet binding sites for the coagulation factors). Since binding
sites change with the concentration of activated platelets, the local
effective reaction rates change as well. For modeling isotropic
coagulation in a well plate, we account for a continuum of platelet
activation states by thrombin and assume an excess of PS once
platelets fully activate (as opposed to discrete saturable binding
sites in the Kuharsky-Fogelson model).
Reactions that have been reported in literature (See Table 1
footnotes) to be accelerated by acidic phospholipids are upregu-
lated in the model when platelets are activated by thrombin as e
increases (and dissociation rates decrease). Platelets provide the
negative surfaces for coagulation factor assembly in vivo, yet most
current enzymology studies of coagulation enzyme kinetics in vitro
use artificial phospholipid surfaces since standardizing platelet
surfaces for kinetic assays is difficult.
In reality, surface adsorption of procoagulant molecules might
also alter the catalytic efficiency (kcat), but for the sake of simplicity
all kcat values are set to their reported values at saturating PS levels
(with the assumption that loose enzyme substrate complexes will
hardly be formed in the first place and thus rarely get converted).
The assumption that all unbinding rates change by two orders of
magnitude is also made for simplicity. (In reality some enzyme
substrate complexes are dramatically strengthened on exposed PS
surfaces, while others show only weak dependence. See Table 1
footnotes.)
We make the assumption that the amount of active surface
available upon activation of platelets at normal platelet counts
(3610
6 platelets per 50 ml reaction well for 56diluted blood with a
platelet count 3610
8 platelets/ml) is sufficient for coagulation
Figure 8. Prevention of initiation on CVX activated platelets. CTI-treated regular plasma or plasma deficient in factors VII, XI or XII were
supplemented with washed (plasma free) platelets. These samples were left untreated or were treated with antibodies against TF; VII; XI; XII or XI, XII
and VII simultaneously; and tested for thrombin generation without exogenous TF addition after activating platelets with 25 nM CVX. Simultaneous
inhibition of XI, XII and VII activity was required to completely abolish thrombin generation.
doi:10.1371/journal.pcbi.1000950.g008
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Hockin-Mann model we assume an excess of phospholipid
surfaces once the platelets are activated. Yet, our approach
accounts for the fact that surface reactions occur at a rate
dependent on the extent of platelet activation rather than being
fixed at the highest level at t=0.
As a pseudohomogeneous and single phase model of coagula-
tion, we do not treat platelets as separate entities (or account for
free and plate bound species). Thus, the fact that each platelet may
have a limited number of specific binding sites is not considered.
Our approach assumes that sufficient binding sites are available in
56diluted blood, an assumption that may not be valid at greater
dilutions. Also, we assume that coagulation in a well plate is well
mixed, lacks spatial gradients, and is not transport-controlled. In
contrast, intravascular thrombosis occurs under conditions with (1)
substantial gradients of reactive species and platelet binding sites,
(2) significant effects of convective transport on soluble species, and
(3) intrathrombic diffusion limitations.
Setting the initial activation state emax0, allows us to control
in simulation the basal level of activation of the platelet
(Figure 11B). For emax0~0:01 (akin to assuming 1% PS exposure
on the surface of unactivated platelets), we obtain a burst in
Figure 9. Titration of TF and active proteases into blood. (A) Effect of exogenous TF on initiation time. TF was titrated from 0.5 fM to
5p Mi n5 6diluted blood. The black solid line is the simulated initiation time for the Hockin-Mann model (with SIIa) and the blue dashed line is the
prediction of the Platelet-Plasma model. The light green solid line is the experimental control with no added TF. (B) Addition of prothrombinase
components. Xa (red) and Va (green) was added to 56diluted blood. The black solid line is the simulated initiation time for the Hockin-Mann model
(with SIIa). The red and green dashed lines are the prediction of the Platelet-Plasma model for Xa and Va, respectively. The light green solid line is the
experimental control with no added proteins. (C) Addition of VIIa, IXa and XIa. Various concentrations of VIIa (green), IXa (red) and XIa (blue) were
added to blood at 56dilution. The dashed lines of the corresponding color are simulations done with the Platelet-Plasma model. The light green
solid line is the experimental control.
doi:10.1371/journal.pcbi.1000950.g009
Figure 10. Simulating clotting times in whole blood. The very small reaction volumes in a 384 well plate prevent us from studying coagulation
reactions in whole blood (See text). To simulate the kinetics of initiation in whole blood we simulated clotting times for additions of TF, thrombin (IIa),
IXa, Xa or combinations of all 3 proteases at low and high doses reported by Butenas et al. [49] in the Mann laboratory. We found good qualitative
agreement between experimental clotting times (blue) and initiation times predicted by the Platelet-Plasma model (green). The Hockin-Mann (with
fluorogenic thrombin substrate, SIIa) model (red) predicts finite initiation times only in the presence of high dose TF or Xa.
doi:10.1371/journal.pcbi.1000950.g010
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,75 min in the Platelet-Plasma model. To simulate experiments
where coagulation reactions occur upon pre-activated platelets,
emax0 is set to a value of 1.0 (with the assumption that the fully
activated platelets have exposed all of their PS) giving Ti,15 min.
These values are in good agreement (Figure 11A) with the mean
initiation times obtained upon unactivated platelets (solid lines) and
activated platelets (dashed lines) for the 4 donors shown in Figure 4.
We note that the rate of thrombin production (substrate
conversion) in simulation beyond Ti increases more sharply than
actually observed in experiment. Thrombin concentrations at
Ti are ,10 nM, corresponding to a fully activated platelet
(Figure 2B) beyond Ti. This suggests that a method of
prothrombinase inhibition (that has not been considered in our
reaction topology) may exist once platelets are activated. Inhibi-
tion of XaVa in vitro in the absence of endothelial thrombomodulin
is poorly understood. Further experiments will be required to
pinpoint this inhibitory mechanism, but for the present the
Platelet-Plasma model is a reliable indicator of the time taken to
generate a burst in thrombin in vitro.
Discussion
Human blood is the only living tissue that is routinely and easily
obtained for in vitro research and clinical diagnostics. Blood is fully
amenable to high throughput functional phenotyping and strong
genotype-phenotype linkages are the basis of significant human
disease. The platelet and the plasma form the basis for hemostasis
and have been modeled from a bottom-up systems biology
approach [18,20,21,51] with the distinct advantage of relatively
well defined reaction topology and freedom from genome-wide
transcriptional complexity.
We have developed a high throughput assay that allowed us to
study thrombin generation in diluted blood, across several
conditions simultaneously with multiple replicates at each
condition. The use of diluted blood in this assay is a limitation
of the small reaction volumes in a 384-well plate and scales the
initial concentrations of all species by the final dilution factor. The
presence of an externally added fluorogenic substrate for the
purpose of detection represents a subtle alteration of thrombin-
mediated feedback of its own generation by competitively
Figure 11. Simulating platelet activation. (A) Mean substrate conversion across all replicates for the donors shown in Figure 4. Substrate
conversion traces without platelet activation are shown in solid lines and conversion traces upon activated platelets are shown in dashed lines. (B)
Setting the initial activation state emax0 ðÞ allows us to simulate platelet activation and its dynamic effect on all platelet dependent unbinding rates (see
methods). The red line indicates simulations of substrate conversion without prior platelet activation emax0~0:01 ðÞ . The blue dashed line indicate
simulations of substrate conversion upon instantaneously fully activated platelets at t=0. emax0~1:0 ðÞ .
doi:10.1371/journal.pcbi.1000950.g011
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used thrombin substrates Z-GGR-MCA and Boc-VPR-MCA
(Figures 3 A, B, C and D). The latter substrate was found to
have acceptably small inhibitory effects on Ti at a concentration of
10 mM. In contrast, Z-GGR-MCA at a concentration of 100 mM
was found to markedly hinder Ti for 1 pM TF triggered
coagulation. The use of 416 mM of this substrate in the ‘Calibrated
Automatic Thrombography’ assay may be necessitated by the
objective of tracing the ‘complete’ thrombogram. The use of
10 mM Boc-VPR-MCA suffices for the purpose of detecting
coagulation ‘initiation’ and reduces assay interference. Also, the
use of citrate as an anticoagulant was not found to have any
significant influence on clot initiation times and permitted us to
have a well defined activation time (t=0) for the coagulation
reaction space defined as the time of recalcification of all the wells.
Effects of the contact factor pathway were significant at
concentrations less than 100 fM TF and were subsequently
prevented by the use of CTI (Figure. 3E).
We and others have consistently observed that CTI-treated
human blood clots in the absence of added TF in vitro. In keeping
with the notion of ‘‘blood borne TF’’ it is tempting to attribute
such clotting initiation to platelet-dependent sources [5,36]. We
explored several possible mechanisms with neutralizing antibodies
against TF, VII/VIIa, PDI, P-selectin, GPIb, and cathepsin G but
none had affect on thrombin generation. Similar to the
experiments of Butenas et al. [52], we have not found any
evidence for functional TF in static whole blood (a closed system).
CTI inhibits b XIIa [53] and has relative specificity for this
form of XIIa [54]. The b form of XIIa does not bind to surfaces
and has little ability to activate XI, although it does activate Pre-
Kallikrein (which in turn amplifies XIIa production). The
effectiveness of CTI in prolonging APTT is probably a result of
prevention of XIIa amplification by Kallikrein produced by b
XIIa. The surface bound a form of XIIa is the main activator of
FXI and the intrinsic coagulation system [55]. Such XIa produced
by a XIIa on negative surfaces could get past CTI and lead to
contact activation. We have demonstrated that in resting whole
blood XIIa can leak past even very high concentrations of CTI,
eventually leading to a significant burst in thrombin production
(Figure 6). Without CVX activation, the combined use of CTI,
anti-XII and anti-XI block all proximal triggers of clotting in the
4 hr assay (Figure 7). With CVX activation, VIIa activity on the
active platelet alone (independent of TF) is kinetically significant,
but the local activity of single molecules of XIa (formed
downstream of a XIIa leak past CTI) in the proximity of the
active platelet surface, can lead to efficient thrombin production
(Figure 8).
We highlight a recent report by Back-Nilsson et al. [56] where
the authors showed that the levels of XIIa-AT, XIa-AT and
Kallikrein-AT complexes were not affected by CTI treatment if
contact activation of XII is allowed to occur on activated platelet
surfaces. In contrast, if contact activation is allowed to occur on
artificial negative surfaces like glass or kaolin, the formation of
XIIa inactivation complexes is completely abolished by CTI (Back
et al. Figures 1–3). Thus, there exists strong evidence that CTI is
ineffective against XIIa formed on active platelet surfaces. Several
reports attribute in vitro thrombin generation following platelet
activation to endogenous TF. Caution must be exercised in
interpreting such results because contact activation contact
activation still occurs upon active platelet surfaces even in the
presence of CTI (and antibodies against XII and XI).
Initiation times obtained by titrations of active proteases provide
estimates of upper limits for endogenous active proteases.
Activation peptides of several proteases have indeed been detected
in blood indicating that these proteases do exist in active form
albeit in concentrations low enough to have little effect on
physiologic time scales [8,9,10,11]. Our experimental titrations
(Figure 9) bounded the initial conditions of active proteases (or
TF) in blood to: ,,500pM Va, ,1 nM VIIa, ,1 pM IXa,
,10 pM Xa, ,1 pM XIa and ,,40 fM of pre-synthesized TF.
Titrations of added thrombin are difficult to deconvolute using
fluorogenic thrombin substrates. Circulating thrombin levels must
be ,100 pM to maintain platelets in an unactivated state
(Figure 2B). With respect to initial conditions of active proteases
at t=0, we attempted to search the initial condition space of blood
using Simulated-Annealing and Particle-Swarm optimization
algorithms to find the best fit of initial conditions, subject to the
above upper bounds for non-zero initial levels of Va, VIIa, IXa,
Xa, XIa and bloodborne TF. Despite more than 100,000
simulations, no acceptable fit was obtained by optimization of
initial conditions alone. Importantly, adjustment of XIa (t=0) was
insufficient to maintain an ‘‘engine idling’’ model of blood
consistent with the results in Figures 9–11. It was necessary to
include a source term that generated XIIa at a rate slow enough to
have little effect on short time scales in the presence of high
concentrations of active proteases, but fast enough to limit Ti to
that of the control. TF independent VIIa activity was found to be
appreciable at high concentrations and upon active platelet
surfaces and was therefore also considered as a proximal trigger
of coagulation initiation.
The estimation of a rate of XIIa production (Reaction 29,
Table 1) allows us to extend the predictive capacity of the
Hockin-Mann model to low concentrations of TF. Further we
were also able to simulate titrations of Va, VIIa, IXa, Xa and XIa
in 56 diluted blood (Figure 9); clotting times observed with
additions of TF, IXa, Xa and thrombin in whole blood
(Figure 10); and the observed consequences of platelet activation
(Figure 11). However, the Platelet-Plasma model remains a
coarse grained platelet and pseudo-homogeneous model. No
distinction is made explicitly between bulk and surface phases and
binding of reactants onto the platelet surface is not considered
separately. Net conversion rates were sped up as the platelet
activates by decreasing the unbinding of the enzyme-substrate
complex (representing the role of anionic lipid exposure), but no
explicit attempt was made to model the change in exposed surface
area and chemistry, and its effect on reaction rates. For the sake of
simplicity, a single functional form (e) was assumed for the changes
in rates as the platelet activates, resulting in a two order change in
rate of all desorption reactions on the platelet surface. We have
shown recently that it is possible to construct donor specific models
of platelet calcium mobilization as a function of combinatorial
agonist concentrations at the site of the thrombus [57]. To
incorporate donor specific descriptions of platelet function in
models of coagulation, the correlation between intracellular
calcium and PS exposure must be defined.
The present study indicates the future feasibility of a full
description of blood accounting for intracellular platelet metabo-
lism and heterogenous reactions on the dynamic platelet surface.
In keeping with the static environment in a well plate and the
absence of endothelium, no consideration was made of fluid flow,
mass transfer from the bulk onto the platelet surface or
thrombomodulin/APC mediated pathways. Our model extends
the topology of the Hockin-Mann structure to better simulate in
vitro clotting initiation of whole blood under diverse initial
conditions, however the assumption of a well mixed static system
is not appropriate for simulations of thrombosis under flow in vivo.
Our high throughput measurement system allows us to rapidly
and reproducibly quantify the duration of the initiation phase
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potential to efficiently identify coagulation pathologies. For
instance, an extended duration of this metric for a donor would
indicate propensity to bleeding diseases like hemophilia while a
shortened metric would indicate predisposition to thrombosis.
Titration experiments with added proteases provide a higher
dimensional examination of blood function than simply measuring
the clotting time after addition of high doses of TF.
Materials and Methods
Ethics statement
Human blood was collected from consenting normal donors in
accordance with the policies of and with the permission of the
University of Pennsylvania Institutional Review Board.
Materials
The fluorogenic thrombin substrates Boc-Val-Pro-Arg-methyl-
coumarinamide (Boc-VPR-MCA) and Z-Gly-Gly-Arg methylcou-
marinamide (Z-GGR-MCA) were obtained from Bachem (King of
Prussia, PA). Lipidated recombinant TF (baculovirus expressed,
amino acids 1–263; 43kDa), monoclonal anti-human FVII/VIIa,
and TF ELISA kits were obtained from American Diagnostica
(Stamford, CT) and used to determine the available TF antigen
concentration of 18.2 nM. Monoclonal anti human FXI and FXII
were obtained from Enzyme Research Laboratories (South bend,
IN). Monoclonal anti human P-selectin was obtained from R&D
Systems (Minneapolis, MN). Monoclonal anti human Gp1ba was
obtained from Lifespan Biosciences (Seattle, WA). Polyclonal anti
human cathepsin-G was obtained from Molecular Innovations
(Novi, MI). Monoclonal anti human PDI was obtained from was
obtained from Affinity Bioreagants (Rockford, IL). Thrombin-
antithrombin ELISA kits were obtained from Dade Behring
(Deerfield, Illinois). Active site inhibited VIIa (VIIai) was gifted by
Novo-Nordisk, Denmark. Other reagents included: adenosine
diphosphate (ADP), benzamidine hydrochloride, EDTA, HEPES,
NaCl, NaOH, sodium citrate, apyrase, PGE2, Tg003 and
Puromycin (all from Sigma, St. Louis, MO); corn trypsin inhibitor
(CTI), Phe-Pro-Arg-chloromethylketone (FPRCK), human a-
thrombin, polyclonal anti-human TF, Xa, Va, VIIa, IXa, XIa,
human plasmas deficient in prothrombin and factors V, VII, XI or
XII (all from Hematological Technologies, Essex Junction, VT);
convulxin (CVX, Centerchem, Norwalk, CT); and black 384-well
plates (Corning, Corning, NY). All reagents were stored and
prepared according to the manufacturers’ recommendations. The
buffer used for all dilutions was HEPES buffered saline (HBS,
sterile filtered 20 mM HEPES and 140 mM NaCl in deionized
water adjusted to pH 7.4 with NaOH).
Blood collection and preparation of washed platelets
Unless otherwise noted, blood was collected in a syringe
containing 1 part sodium citrate to 9 parts blood and 50 mg CTI/
mL. To obtain washed platelets for the experiments in Figure 8,
blood was first centrifuged at 120g for 12 min to obtain platelet
rich plasma (PRP). PRP was then treated with 200mM PGE2 and
1unit/ml apyrase to prevent activation during subsequent
spinning. A platelet pellet was obtained by centrifuging PRP at
800g for 10 min and this pellet was resuspended in HBS to yield a
final concentration of ,3610
8 platelets/ml.
High throughput experimentation
Prior to phlebotomy, all reagents were prepared in a 384-well
plate using a Thermo Multidrop and a Perkin-Elmer JANUS
workstation. For all experiments, blood was added to the whole (or
segments) of a well plate using a PerkinElmer Evolution P
3.T o
ensure a simultaneous activation time, citrated blood was
recalcified in all 384 wells simultaneously, yielding a final added
calcium concentration of 10 mM. To detect thrombin activity
with time, we added the fluorogenic substrate (SIIa), Boc-VPR-
MCA (10 mM) to every well and detected the fluorescence of the
released aminomethylcoumarin (AMC) with Thermo Fluoroskan
fluorimeters preheated to 37uC. Each well was read once per
minute for 4 hr. After 4 hours, 5 U thrombin/well was added and
then the plate was read again once per minute for 20 minutes to
determine the maximal signal. In experiments to study the effect of
fluorogenic substrate concentration, Boc-VPR-MCA or Z-GGR-
MCA were used at final concentrations between 1 and 100 mM.
All experiments were carried out in 56 diluted whole blood.
Fractional conversion of the fluorogenic substrate was determined
according to:
C~
F{Fmin
Fmax{Fmin
ð1Þ
where C is the fractional conversion, F is the instantaneous
fluorescence at any time, Fmin is the minimum fluorescence for that
well, and Fmax is the maximum fluorescence in that well during
either the experiment or after thrombin addition. The initiation
time (Ti) was set when C rises past 0.05.
Thrombin-Antithrombin (TAT) immunoassays
TAT serves as a measure of the cumulative thrombin
production. Citrated blood was dispensed into all wells of a 384-
well plate containing calcium using a PerkinElmer Evolution P
3
liquid handling station. Reactions were manually stopped in
columns of the well plate by adding a ‘stop cocktail’ of 50 mM
EDTA, 20 mM benzamidine and 100 mM Phe-Pro-Arg-chlor-
omoethyl ketone (PPACK) at specific time points [58]. The plate
was spun at 120g for 12 min to separate out plasma, which was
subsequently assayed for TAT by ELISA (Dade Behring).
Simulation
Simulations were performed in Matlab R2008b (version
7.7.0.471) using the Systems Biology Toolbox 2 (SBTOOLBOX2)
with the SBPD extension package ODE solver with an absolute
tolerance of 10
230 and a relative tolerance of 10
27 [59].
A function of thrombin concentration was fit with a Hill
function to published experimental data that quantified ‘Platelet
Activation Status’ by reporting surface Phosphatidylserine expo-
sure (measured by fold increase in Annexin V binding) in response
to thrombin (IIa) [60] (Figure. 2B):
f IIa   t ðÞ ½  ðÞ ~
IIa   t ðÞ ½ 
1:6123
IIa   t ðÞ ½ 
1:6123z 2:4279|10{9 ðÞ
1:6123 ð2Þ
where IIa   t ðÞ ½  ~max
t0 0 t ½ 
IIa t0 ðÞ ½  ðÞ . Since thrombin concentration
physiologically starts decreasing after monotonically rising to a
peak, it was necessary to use the maximum transient thrombin
concentration, max
t0 0 t ½ 
IIa t0 ðÞ ½  ðÞ , to ensure that f IIa   t ðÞ ½  ðÞ never
decreases once it has reached its maximum magnitude. IIa   t ðÞ ½ 
is exactly equivalent to [IIa(t)] until [IIa(t)] reaches its peak value,
whereafter IIa   t ðÞ ½  remains constant at that maximum value.
This ensures that the platelet stays activated even when thrombin
levels decline.
Systems Biology of Coagulation Initiation
PLoS Computational Biology | www.ploscompbiol.org 21 September 2010 | Volume 6 | Issue 9 | e1000950For a given [IIa], we define the maximum platelet activation
state, emax:
emax~emax0z 1{emax0

|f IIa   t ðÞ ½  ðÞð 3Þ
where emax describes the fractional activation state of the platelet.
emax0 defines the basal activation state of the platelet at t=0, and is
set to 0.01 in most simulations (assuming a basal 1% binding
strength of coagulation factors to the resting platelet surface). For
full activation of platelets at [thrombin] .,10 nM, emax equals 1
and protein dissociation is minimized.
The instantaneous platelet activation state e is governed by the
differential equation
de
dt
~k emax{e ðÞ ð 4Þ
with the initial condition at t~0, e~0:01, this solves to,
e~emax{ emax{0:01 ðÞ |exp {kt ðÞ ð 5Þ
The constant k is inversely proportional to the time scale of platelet
activation, and was set to 0.005. This is consistent with the fact
that it takes ,200 s for platelets to mobilize calcium from
intracellular stores upon stimulation with thrombin or other
platelet agonists [57]. Such a form of the platelet function (e)
ensures that the platelet achieves its maximum attainable
activation state (emax) not instantaneously, but on a physiologically
relevant timescale. Transients of e are shown for values of
emax=0.25, 0.5, 0.75 and 1.0 are shown in Figure 2c.
To account for changes in the reaction rates with platelet
activation, we modified the Hockin-Mann model rate constants as
follows,
kmodified~koriginal| g=e ðÞ ð 6Þ
where g was a parameter that was used to alter the magnitude of
the rate constant used in the Hockin-Mann model. Many of the
Hockin-Mann model parameters were originally fitted empirically
to global experimental data. For g=1 and full platelet activation
(e=1), the modified value becomes the original value. For g ? 1,
the modifications may be regarded as further fits to experimental
data, consistent with published values of rate constants (footnotes
to Table I).
To estimate the sensitivity of our model’s output to the choice of
kinetic constants, a global sensitivity analysis of the models output
thrombin concentration at 0 and 10 pM TF concentration was
carried out by the method of weighted averaging of local
sensitivities. The results of this analysis are shown in Figure
S1A and Figure S1B in Text S1, and Table S1 and Table S2
in Text S1. Local sensitivity of Ti to 10 fold variations in
important parameters (determined from the global sensitivity
analysis) across the entire range of titrated TF concentrations is
shown in Figure S1 C in Text S1.
Supporting Information
Text S1 A complete description of the ODEs for all 76 species in
the assembled reaction network, along with the definition of every
reaction rate. Essentially all of the model parameters (rate
constants and initial conditions) are known or estimated from
literature (Table 1). The use of g clarifies changes from the
original Hockin-Mann rate constants that are justified by more
recent literature measurements (See Table 1 footnotes). Only, the
rate of XIIa leakage was estimated (i.e. fitted) based on the
difference between simulation and experiment at 0 added T.
Found at: doi:10.1371/journal.pcbi.1000950.s001 (0.54 MB
DOC)
Author Contributions
Supervised all research: SLD. Constructed the platelet plasma model and
performed the well-plate experiments in Figures 3–8: MSC. Performed the
sensitivity analysis in Figure S1 in Text S1: MSC. Performed the TAT
ELISAs to validate the fluorogenic assay (Figures 3C, D): MSC HJ. Wrote
the paper with contributions from all authors: MSC. Performed the well-
plate experiments titrating active proteases into blood (Figure 9): WSD.
References
1. Rand MD, Lock JB, van’t Veer C, Gaffney DP, Mann KG (1996) Blood clotting
in minimally altered whole blood. Blood 88: 3432–3445.
2. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG (2005) The tissue factor
requirement in blood coagulation. J Biol Chem 280: 42887–42896.
3. Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, et al. (1999) Blood-borne
tissue factor:Anotherview of thrombosis. Proc Natl AcadSciU SA 96:2311–2315.
4. Butenas S, Orfeo T, Mann KG (2009) Tissue Factor in Coagulation: Which?
Where? When? Arterioscler Thromb Vasc Biol 29: 1989–1996.
5. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, et al. (2007) Human platelets
synthesize and express functional tissue factor. Blood 109: 5242–5250.
6. Bach RR (2006) Tissue Factor Encryption. Arterioscler Thromb Vasc Biol 26:
456–461.
7. Morrissey JH, Pureza V, Davis-Harrison RL, Sligar SG, Ohkubo YZ, et al.
(2008) Blood clotting reactions on nanoscale phospholipid bilayers. Thromb Res
122: S23–S26.
8. Bauer KA, Goodman TL, Kass BL, Rosenberg RD (1985) Elevated factor Xa
activity in the blood of asymptomatic patients with congenital antithrombin
deficiency. J Clin Invest 76: 826–836.
9. Cardigan RA, Crook M, Mackie IJ, Machin SJ (2001) Plasma levels of factor
XIIa and factor VIIa are increased but not related in primary hyperlipidaemia.
Blood Coagul Fibrinolysis 12: 187–192.
10. Nossel HL, Yudelman I, Canfield RE, Butler VP, Jr., Spanondis K, et al. (1974)
Measurement of fibrinopeptide A in human blood. J Clin Invest 54: 43–53.
11. Shifman MA, Pizzo SV (1982) The in vivo metabolism of antithrombin III and
antithrombin III complexes. J Biol Chem 257: 3243–3248.
12. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S (1990)
Surface-Dependent Reactions of the Vitamin-K-Dependent Enzyme Complex-
es. Blood 76: 1–16.
13. Hemker HC (2008) Recollections on thrombin generation. J Thromb Haemost
6: 219–226.
14. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, et al. (2003)
Calibrated automated thrombin generation measurement in clotting plasma.
Pathophysiology of Haemostasis and Thrombosis 33: 4–15.
15. Butenas S, Mann KG (2007) Caution in the interpretation of continuous
thrombin generation assays. J Thromb Haemost 5: 1084–1085.
16. Mann KG, Whelihan MF, Butenas S, Orfeo T (2007) Citrate anticoagula-
tion and the dynamics of thrombin generation. J Thromb Haemost 5: 2055–
2061.
17. Hojima Y, Pierce JV, Pisano JJ (1980) Hageman factor fragment inhibitor in
corn seeds: Purification and characterization. Thromb Res 20: 149–162.
18. Hockin MF, Jones KC, Everse SJ, Mann KG (2002) A model for the
stoichiometric regulation of blood coagulation. J Biol Chem 277: 18322–18333.
19. Lo K, Denney WS, Diamond SL (2005) Stochastic modeling of blood
coagulation initiation. Pathophysiol Haemost Thromb 34: 80–90.
20. Kuharsky AL, Fogelson AL (2001) Surface-Mediated Control of Blood
Coagulation: The Role of Binding Site Densities and Platelet Deposition.
Biophys J 80: 1050–1074.
21. Luan D, Zai M, Varner JD (2007) Computationally derived points of fragility of
a human cascade are consistent with current therapeutic strategies. Plos Comput
Biol 3: 1347–1359.
22. Hemker HC, De Smedt E (2007) Caution in the interpretation of continuous
thrombin generation assays: a rebuttal. J Thromb Haemost 5: 1085–1087.
23. Gosalia DN, Denney WS, Salisbury CM, Ellman JA, Diamond SL (2006)
Functional phenotyping of human plasma using a 361-fluorogenic substrate
biosensing microarray. Biotechnol Bioeng.
24. Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for?
J Thromb Haemost 1: 1504–1514.
25. Van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, et al. (2008) Corn
trypsin inhibitor in fluorogenic thrombin-generation measurements is only
necessary at low tissue factor concentrations and influences the relationship
Systems Biology of Coagulation Initiation
PLoS Computational Biology | www.ploscompbiol.org 22 September 2010 | Volume 6 | Issue 9 | e1000950between factor VIII coagulant activity and thrombogram parameters. Blood
Coagul Fibrinolysis 19: 183–189.
26. del Conde I, Nabi F, Tonda R, Thiagarajan P, Lopez JA, et al. (2005) Effect of
P-Selectin on Phosphatidylserine Exposure and Surface-Dependent Thrombin
Generation on Monocytes. Arterioscler Thromb Vasc Biol 25: 1065–1070.
27. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, et al. (1994) P-selectin
induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A
91: 8767–8771.
28. Polgar J, Matuskova J, Wagner DD (2005) The P-selectin, tissue factor,
coagulation triad. J Thromb Haemost 3: 1590–1596.
29. Dougald MM, Maureane H, Julie AO, Harold RR (1997) Platelet activity of
high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:
542–547.
30. Weeterings C, de Groot PG, Adelmeijer J, Lisman T (2008) The glycoprotein Ib-
IX-V complex contributes to tissue factor-independent thrombin generation by
recombinant factor VIIa on the activated platelet surface. Blood 112:
3227–3233.
31. Chen K, Lin Y, Detwiler TC (1992) Protein disulfide isomerase activity is
released by activated platelets. Blood 79: 2226–2228.
32. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, et al. (2006) Evidence
for Activation of Tissue Factor by an Allosteric Disulfide Bond. Biochemistry 45:
12020–12028.
33. Reinhardt C (2008) Protein disulfide isomerase acts as an injury response signal
that enhances fibrin generation via tissue factor activation. J Clin Invest 118:
1110–1122.
34. Pendurthi UR, Ghosh S, Mandal SK, Rao LVM (2007) Tissue factor activation:
is disulfide bond switching a regulatory mechanism? Blood 110: 3900–3908.
35. Plescia J, Altieri DC (1996) Activation of Mac-1 (CD11b/CD18)-bound factor X
by released cathepsin G defines an alternative pathway of leucocyte initiation of
coagulation. Biochem J 319: 873–879.
36. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, et al. (2006)
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombo-
genecity of human platelets. J Exp Med 203: 2433–2440.
37. Karas SP, Rosse WF, Kurlander RJ (1982) Characterization of the IgG-Fc
receptor on human platelets. Blood 60: 1277–1282.
38. von dem Borne PA, Meijers JC, Bouma BN (1995) Feedback activation of factor
XI by thrombin in plasma results in additional formation of thrombin that
protects fibrin clots from fibrinolysis. Blood 86: 3035–3042.
39. Okorie UM, Denney WS, Chatterjee MS, Neeves KB, Diamond SL (2008)
Determination of surface tissue factor thresholds that trigger coagulation at
venous and arterial shear rates: amplification of 100 fM circulating tissue factor
requires flow. Blood 111: 3507–3513.
40. Fogelson AL, Tania N (2005) Coagulation under flow: the influence of flow-
mediated transport on the initiation and inhibition of coagulation. Pathophysiol
Haemost Thromb 34: 91–108.
41. Camire RM, Pollak ES, Kaushansky K, Tracy PB (1998) Secretable human
platelet-derived factor V originates from the plasma pool. Blood 92: 3035–3041.
42. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, et al. (1992)
Measurement of Basal Levels of Factor-Viia in Hemophilia-a and Hemophilia-B
Patients. Blood 80: 25–28.
43. Macik BG, Hohneker J, Roberts HR, Griffin AM (1989) Use of recombinant
activated factor VII for treatment of a retropharyngeal hemorrhage in a
hemophilic patient with a high titer inhibitor. Am J Hematol 32: 232–234.
44. Bouma BN, Griffin JH (1977) Human-Blood Coagulation Factor-Xi -
Purification, Properties, and Mechanism of Activation by Activated Factor-
Xii. J Biol Chem 252: 6432–6437.
45. Naito K, Fujikawa K (1991) Activation of human blood coagulation factor XI
independent of factor XII. Factor XI is activated by thrombin and factor XIa in
the presence of negatively charged surfaces. J Biol Chem 266: 7353–7358.
46. Kramoroff A, Nigretto JM (2001) In vitro factor XI activation mechanism
according to an optimized model of activated partial thromboplastin time test.
Blood Coagul Fibrinolysis 12: 289–299.
47. Naski MC, Shafer JA (1991) A kinetic model for the alpha-thrombin-catalyzed
conversion of plasma levels of fibrinogen to fibrin in the presence of
antithrombin III. J Biol Chem 266: 13003–13010.
48. De Smedt E, Wagenvoord R, Hemker HC (2009) The technique of measuring
thrombin generation with fluorogenic substrates: 3. The effects of sample
dilution. Thromb Haemost 101: 165–170.
49. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG (2004) The
Significance of Circulating Factor IXa in Blood. J Biol Chem 279:
22875–22882.
50. Xu Z, Lioi J, Mu J, Kamocka MM, Liu X, et al. A Multiscale Model of Venous
Thrombus Formation with Surface-Mediated Control of Blood Coagulation
Cascade. 98: 1723–1732.
51. Purvis JE, Chatterjee MS, Brass LF, Diamond SL (2008) A molecular signaling
model of platelet phosphoinositide and calcium regulation during homeostasis
and P2Y1 activation. Blood 112: 4069–4079.
52. Butenas S, Mann KG (2004) Active tissue factor in blood? Nat Med 10:
1155–1156.
53. Hazegh-Azam M, Kim SS, Masoud S, Andersson L, White F, et al. (1998) The
corn inhibitor of activated hageman factor: Purification and properties of two
recombinant forms of the protein. Protein Expression and Purification 13:
143–149.
54. Sanchez J, Elgue G, Riesenfeld J, Olsson P (1998) Studies of adsorption,
activation, and inhibition of factor XII on immobilized heparin. Thromb Res
89: 41–50.
55. Revak SD, Cochrane CG, Bouma BN, Griffin JH (1978) Surface and fluid phase
activities of two forms of activated Hageman factor produced during contact
activation of plasma. J Exp Med 147: 719–729.
56. Back J, Lang MH, Elgue G, Kalbitz M, Sanchez J, et al. (2009) Distinctive
regulation of contact activation by antithrombin and C1-inhibitor on activated
platelets and material surfaces. Biomaterials 30: 6573–6580.
57. Chatterjee MS, Purvis JE, Brass LF, Diamond SL Pairwise agonist scanning
predicts cellular signaling responses to combinatorial stimuli. Nat Biotech 28:
727–732.
58. Brummel KE, Paradis SG, Branda RF, Mann KG (2001) Oral anticoagulation
thresholds. Circulation 104: 2311–2317.
59. Schmidt H, Jirstrand M (2006) Systems Biology Toolbox for MATLAB: a
computational platform for research in systems biology. Bioinformatics 22:
514–515.
60. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, et al. (1999)
Protease-activated receptor 1 is the primary mediator of thrombin-stimulated
platelet procoagulant activity. Proc Natl Acad Sci U S A 96: 11189–11193.
61. Bach R, Gentry R, Nemerson Y (1986) Factor-VII Binding to Tissue Factor in
Reconstituted Phospholipid-Vesicles - Induction of Cooperativity by Phospha-
tidylserine. Biochemistry 25: 4007–4020.
62. O’Brien DP, Kemball-Cook G, Hutchinson AM, Martin DM, Johnson DJ, et al.
(1994) Surface plasmon resonance studies of the interaction between factor VII
and tissue factor. Demonstration of defective tissue factor binding in a variant
FVII molecule (FVII-R79Q). Biochemistry 33: 14162–14169.
63. Shaw AW, Pureza VS, Sligar SG, Morrissey JH (2007) The local phospholipid
environment modulates the activation of blood clotting. J Biol Chem 282:
6556–6563.
64. Baugh RJ, Broze GJ, Jr., Krishnaswamy S (1998) Regulation of extrinsic
pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem
273: 4378–4386.
65. Hathcock JJ, Rusinova E, Gentry RD, Andree H, Nemerson Y (2005)
Phospholipid regulates the activation of factor X by tissue factor/factor VIIa
(TF/VIIa) via substrate and product interactions. Biochemistry 44: 8187–8197.
66. Beals JM, Castellino FJ (1986) The Interaction of Bovine Factor-IX, Its
Activation Intermediate, Factor-IX-Alpha, and Its Activation Products, Factor-
IXa-Alpha and Factor-IXa-Beta, with Acidic Phospholipid-Vesicles of Various
Compositions. Biochem J 236: 861–869.
67. Jenkins PV, Dill JL, Zhou Q, Fay PJ (2004) Contribution of factor VIIIa A2 and
A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry 43:
5094–5101.
68. Neuenschwander P, Jesty J (1988) A comparison of phospholipid and platelets in
the activation of human factor VIII by thrombin and factor Xa, and in the
activation of factor X. Blood 72: 1761–1770.
69. Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN (1990) Kinetics of
coagulation factor X activation by platelet-bound factor IXa. Biochemistry 29:
2606–2611.
70. Fay PJ, Smudzin TM (1992) Characterization of the interaction between the A2
subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 267:
13246–13250.
71. Fay PJ, Mastri M, Koszelak ME (2001) Factor VIIIa cofactor activity shows
enhanced ionic strength sensitivity in the absence of phospholipid. Biochim
Biophys Acta 1548: 159–168.
72. Lindhout T, Goversriemslag JWP, Vandewaart P, Hemker HC, Rosing J (1982)
Factor-Va Factor-Xa Interaction - Effects of Phospholipid-Vesicles of Varying
Composition. Biochemistry 21: 5494–5502.
73. Rosing J, Tans G, Goversriemslag JWP, Zwaal RFA, Hemker HC (1980) Role
of Phospholipids and Factor-Va in the Prothrombinase Complex. J Biol Chem
255: 274–283.
74. Huang ZF, Wun TC, Broze GJ (1993) Kinetics of Factor-Xa Inhibition by
Tissue Factor Pathway Inhibitor. J Biol Chem 268: 26950–26955.
75. Tankersley DL, Finlayson JS (1984) Kinetics of activation and autoactivation of
human factor XII. Biochemistry 23: 273–279.
76. Griep MA, Fujikawa K, Nelsestuen GL (1985) Binding and activation properties
of human factor XII, prekallikrein and derived peptides with acidic lipid vesicles.
Biochemistry 24: 4124–4130.
77. Inger S (1988) Inositolphospholipid-accelerated activation of prekallikrein by
activated factor XII and its inhibition by &#x03B2;2-glycoprotein I.
Eur J Biochem 176: 629–636.
78. Walsh PN, Griffin JH (1981) Contributions of human platelets to the proteolytic
activation of blood coagulation factors XII and XI. Blood 57: 106–118.
79. Tans G, Rosing J, Berrettini M, LA ˜¤mmle B, Griffin JH (1987) Autoactivation
of human plasma prekallikrein. J Biol Chem 262: 11308–11314.
80. van der Graaf F, Koedam JA, Bouma BN (1983) Inactivation of kallikrein in
human plasma. J Clin Invest 71: 149–158.
81. Pixley RA, Schapira M, Colman RW (1985) The Regulation of Human Factor-
Xiia by Plasma Proteinase-Inhibitors. J Biol Chem 260: 1723–1729.
82. Gailani D, Broze GJ, Jr. (1991) Factor XI activation in a revised model of blood
coagulation. Science 253: 909–912.
83. Oliver JA, Monroe DM, Roberts HR, Hoffman M (1999) Thrombin activates
factor XI on activated platelets in the absence of factor XII. Arterioscler
Thromb Vasc Biol 19: 170–177.
Systems Biology of Coagulation Initiation
PLoS Computational Biology | www.ploscompbiol.org 23 September 2010 | Volume 6 | Issue 9 | e100095084. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, et al. (1996)
Modulation of contact system proteases by glycosaminoglycans. Selective
enhancement of the inhibition of factor XIa. J Biol Chem 271: 12913–12918.
85. Walsh PN, Bradford H, Sinha D, Piperno JR, Tuszynski GP (1984) Kinetics of
the Factor XIa catalyzed activation of human blood coagulation Factor IX.
J Clin Invest 73: 1392–1399.
86. Gailani D, Ho D, Sun MF, Cheng QF, Walsh PN (2001) Model for a factor IX
activation complex on blood platelets: dimeric conformation of factor IXa is
essential. Blood 97: 3117–3122.
87. Scandura JM, Walsh PN (1996) Factor X Bound to the Surface of Activated
Human Platelets Is Preferentially Activated by Platelet-Bound Factor IXaa ˆJ
Biochemistry 35: 8903–8913.
88. Wilkinson FH, Ahmad SS, Walsh PN (2002) The Factor IXa Second Epidermal
Growth Factor (EGF2) Domain Mediates Platelet Binding and Assembly of the
Factor X Activating Complex. J Biol Chem 277: 5734–5741.
89. Leipold RJ, Bozarth TA, Racanelli AL, Dicker IB (1995) Mathematical Model of
Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin. J Biol
Chem 270: 25383–25387.
90. Lollar P, Knutson GJ, Fass DN (1985) Activation of porcine factor VIII:C by
thrombin and factor Xa. Biochemistry 24: 8056–8064.
91. Komiyama Y, Pedersen AH, Kisiel W (1990) Proteolytic activation of human
factors IX and X by recombinant human factor VIIa: effects of calcium,
phospholipids, and tissue factor. Biochemistry 29: 9418–9425.
92. Colman RW, Schmaier AH (1997) Contact System: A Vascular Biology
Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflam-
matory Attributes. Blood 90: 3819–3843.
93. Colman R, Hirsh J, Marder V, Clowes A, George J (2001) Hemostasis and
Thrombosis: Lippincott Williams and Wilkins.
Systems Biology of Coagulation Initiation
PLoS Computational Biology | www.ploscompbiol.org 24 September 2010 | Volume 6 | Issue 9 | e1000950